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Intracellular delivery of extracellular cargo into stem cells is an active area of research with 
enormous potential in field of regenerative medicine. Different types of cargo can be delivered, 
including genetic materials (DNA, RNA, siRNA), proteins, and small molecules that are not 
permeable to the cell membrane. Based on the macromolecule delivered, it is possible to directly 
control stem cell gene expression, activate specific intracellular pathways, or induce the secretion 
of therapeutic growth factors. Over the years, several strategies have been investigated to promote 
efficient internalization of external cargos, and they can be subdivided into two main groups 
according to the method of delivery. In the first category, we commonly include carrier-based 
approaches where the physical and chemical properties of the carrier dictate the route of 
internalization and the delivery efficiency. Aside from the carrier, the cell microenvironment can 
also impact the process of internalization when using these strategies. Additionally, several 
parameters such as chemistry, stiffness, and topography of the cell-substrate need to be properly 
selected for efficient delivery of the external cargo. 
The second group consists of all the other possible carrier-free based strategies that aim to promote 
intracellular delivery by increasing the permeability of the cell membrane. Transient pores can be 
induced in the cell membrane by using different physical and mechanical methods that enable the 
passive diffusion of extracellular cargo. In this case, the method of permeabilization should not be 
harmful to the cell and should not elicit any permanent damage to the plasma membrane.  
Based on these scientific premises, which will be discussed in detail in Chapter 1, the aim of this 
thesis was to investigate both types of delivery methods to identify novel approaches for effective 
intracellular delivery of genes as well as small polar molecules into stem cells using human 
adipose-derived stem cells (hASCs) as a model cell line. The overall work of this thesis is 
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subdivided into two separate sections based on the strategy adopted for the delivery of the external 
cargo.  
The first part of the thesis, discussed in Chapter 2, aimed to investigate the modulatory role of 
substrate stiffness in the transfection of stem cells by using conventional lipid-based carriers 
complexed with plasmid DNA (lipoplexes). Precisely, we investigated whether the changes in 
cellular morphology and cytoskeletal rearrangement, induced by a variation in the stiffness of the 
cell-substrate, had any significant impact on the process of transfection. The findings of this work 
are important to advance the understanding of how the physical properties of the cell 
microenvironment can be controlled to enhance the efficacy of conventional carrier-based 
strategies for the transfection of stem cells.  
The second part of the thesis, discussed in Chapter 3 and 4,  was focused on the design of a novel 
carrier-free approach for the intracellular delivery of small polar molecules, such as trehalose. 
Trehalose is a cryoprotecting agent (CPA) that could be used as a replacement of more toxic 
molecules such as dimethylsulfoxide (DMSO). However, the poor permeability of trehalose 
through cell membranes limits its applicability as a CPA for stem cell banking applications. 
Therefore, to promote efficient intracellular delivery of trehalose, we fabricated and optimized a 
microfluidic device that could create temporary pores in the cell membranes to enable the uptake 
of extracellular cargo without the use of any carrier. The safety and efficiency of this new platform 
were tested by studying several parameters, including cell viability, apoptosis, cellular 
morphology, and differentiation potential of hASCs loaded with trehalose after cryopreservation. 
Overall, the results and findings of this final section of the thesis provide a novel valuable strategy 
for the internalization of trehalose to promote efficient cryopreservation of stem cells without the 
use of DMSO. 
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CHAPTER 1. Introduction to the thesis 
 
1. Background 
The plasma membrane is a selective barrier that defines the cell boundaries and maintains a precise 
balance between the cytoplasm and the extracellular environment. It is essentially composed of a 
lipid bilayer that provides the basic fluid structure, which is generally permeable to gases, and few 
solvents such as water, ethanol, and dimethylsulfoxide. The permeability across the membrane 
strictly depends on the properties of the membrane such as thickness, lipid composition, presence 
of proteins, as well as the size and charge of the cargo delivered [1, 2].  
The functions of the cell membrane are dictated by its structure and basic components. The main 
categories of lipids commonly found in the plasma membrane are glycerophospholipids, 
sphingolipids, and sterols. Cholesterol is the main sterol present in the plasma membranes of 
mammalian cells that serves the role as a filler to stiffen and thicken the plasma membrane [3]. 
The lipid composition of the bilayer is highly regulated, displaying both an asymmetrical 
distribution of phospholipids between the intracellular and extracellular layers, as well as the 
presence of specific lipid domains [4]. The lipid bilayer is also a dynamic system, normally defined 
as two-dimensional fluid, and its asymmetrical composition regulates the transmission of 
extracellular signals into intracellular ones. For example, the cytosol layer of the membrane is 
generally enriched with the negatively charged phosphatidylserine, and many cytosolic proteins 
bind to this side of the bilayer to initiate a cascade of intracellular signals. Aside from the 
phospholipids, proteins make up for 50% of the weight of a plasma membrane. Proteins, such as 
receptors, transporters, and enzymes, regulate most of the functions of the cell membrane including 
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regulation of the intracellular ionic concentration of Na+ and K+, transport of polar molecules, and 
catalysis of membrane-associated reactions such as the synthesis of adenosine triphosphate.  
Understanding the structure and functions of the plasma membrane is essential to design efficient 
intracellular delivery strategies [5]. In this introductory chapter, we will discuss two of the main 
approaches that have been investigated by researchers to deliver extracellular cargo into the cell 
and bypass the selective barrier offered by the plasma membrane. These two methods, which have 
been the main object of investigation in this thesis, include carrier-based and carrier-free strategies 
(Figure 1.1). 
 
The former approach involves the use of a carrier that can be internalized by cells through 
endocytosis pathways. Firstly, we will discuss the different steps a carrier undergoes when 
internalized into the cytosol with an emphasis on the delivery of genetic material. We will also 
 
Figure 1.1 Schematic summarizing the main strategies to promote internalization of 
extracellular cargo. Carrier-based and membrane disruption methods are the two main 
categories for effective intracellular delivery Reprinted with permission from [142]. Copyright 





provide an overview of the available carrier-based strategies for gene delivery into stem cells, 
highlighting the key parameters that need to be considered for efficient transfection.  
Next, the focus will be shifted towards the second strategy of this thesis by describing the physical 
and mechanical methods that are commonly used to disrupt the cell membrane and facilitate the 
delivery of extracellular cargo (proteins, DNA and polymers) without the use of any carrier.  
 
1.1 Intracellular delivery of genetic materials 
The modulation of gene expression in stem cells is commonly carried out by introducing 
exogenous nucleic acids such as DNA (plasmid DNA), RNA, small interfering RNA (siRNA), and 
microRNA (mRNA) [6]. To be effectively expressed, these genetic macromolecules should reach 
the nucleus after passing through the plasma membrane [7]. The ideal carrier should deliver an 
appropriate amount of genetic material into the nucleus of the host cell without causing toxicity. 
However, the relatively large size and negative charge of the genetic material pose a significant 
hurdle on the successful internalization and intracellular trafficking to the nuclueus. Their 
internalization can be achieved using different types of carriers that will be discussed more in detail 
in section 1.2 of this chapter. However, irrespective of the type of carrier used for the delivery of 
genes the whole process can be subdivided into five common steps which are: 1) binding of the 
carrier to the cell membrane; 2) endocytosis, 3) endosomolysis, 4) cytosolic transport toward the 
nucleus, and 5) nucleus entry. An efficient carrier system for gene delivery must overcome all the 
obstacles encountered after internalization and guide the translocation of the genetic material to 





1.1.1 Cell binding to the cell membrane 
Carriers for intracellular gene delivery can be designed to promote selective binding to receptors 
or  establish non-specific interactions with the cell membrane by taking advantage of its superficial 
properties. For example, the extracellular side of many plasma membranes is glycosylated, 
meaning that lipids and proteins of the membranes are covalently bound to carbohydrate chains to 
form glycolipids and glycoproteins, respectively. The role of this carbohydrate layer is to protect 
the cell against mechanical damage, to avoid cell-cell interactions or to establish direct contact 
with other proteins of the extracellular matrix. One of the most negatively charged components of 
the cell surface is represented by sulfated proteoglycans that covalently bind to one or more 
sulfated glycosaminoglycans present in the extracellular matrix. These highly anionic chains are 
the target site for carriers with a net positive charge, such as lipoplexes and polyplexes [8]. 
Cationic carriers transporting DNA or RNA have been extensively used to bind electrostatically 
to the highly anionic proteoglycans present on the cell surface. In one study, pre-treating of HeLa 
cells with glycosaminoglycan sulfation inhibitors such as sodium chlorate suppressed the 
luciferase reporter gene expression up to 70% compared to the untreated cells [9]. In another study, 
it was shown that Raji cells, which lack proteoglycans, could not be transfected by lipoplexes 
unless the cells were modified to express the proteoglycan, syndecan-1[10]. The authors also 
suggested that the transfection efficiency was highly dependent on a net positive charge of the 
lipoplex. Overall, these evidence suggests that the presence of proteoglycan can mediate the first 
step of cell binding and that modulation of proteoglycan expression is one of the key targets to 





1.1.2 Activation of specific endocytosis pathways  
After the initial binding step on the cell surface, carriers are generally internalized into cells via 
different endocytosis pathways. The size of the lipoplexes and polyplexes dictates the main 
pathway of internalization, which can occur through clathrin or caveolae-mediated endocytosis 
(Figure 1.2).  
 
Clathrin-mediated endocytosis is activated in the case of carriers that require specific binding to 
transmembrane receptors [11]. The binding process triggers the localization of clathrin structures 
on the intracellular layer of the plasma membrane, which leads to the formation of clathrin-coated 
 
Figure 1.2 Schematic representing the main components of the caveolae machinery necessary to 





pits. The main components of these pits are heavy and light chains of clathrin proteins which are 
assembled into three-legged triskelions commonly linked to adapter proteins [12]. Subsequently, 
the coated pit starts to pinch off from the plasma membrane by the guanidine triphosphates 
GTPase, dynamin. An ATP-dependent enzyme is then responsible for uncoating the vesicles [13].  
It has been shown that nanocarriers with a diameter of less than 200 nm are mainly endocytosed 
via this pathway in non-phagocytic cells. On the contrary, nanomaterials with a diameter of about 
500 nm are commonly internalized by caveolae-mediated endocytosis [14]. Aside from the size, 
the net charge, and the final configuration of the complex also play essential roles in defining the 
main selected pathway for the endocytosis of lipoplexes and polyplexes [15]. For instance, Billiet 
et al. showed that positively charged lipoplexes are mainly internalized by clathrin pathway, while 
negatively charged lipoplexes enter myoblasts via caveolae-mediated endocytosis [16]. 
This alternative pathway is mediated by the presence of caveolae, which are invaginations in the 
plasma membrane displaying transmembrane proteins named as caveolins. These flask-shaped 
invaginations are also rich in cholesterol and sphingolipids and are found on the surface of different 
type of cells, including muscle cells, endothelial cells, and adipocytes [12, 17]. Caveolae formation 
is modulated by caveolins with the help of another group of proteins termed as cavins [18]. 
Caveolae-mediated endocytosis is a microtubule and actin-dependent process. Caveolae are 
stabilized on the cell surface by cortical actin filaments. Disruption of these filaments by 
latrunculin A enhances the internalization of caveolar vesicles and their subsequent intracellular 
transportation [19]. Organization and trafficking of caveolae are influenced by actin stress fibers, 
which are composed of contractile actomyosin bundles. The linkage between caveolae and actin 
stress fibers require the presence of Ras homolog gene family member A (RhoA), actin 
cytoskeleton, and filamin A (an actin-binding protein) [20, 21]. The fate of the pinched off caveola 
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is cell type-dependent. In non-endothelial cells, the cargo is delivered to endolysosomal 
compartments whereas in endothelial cells, especially in vivo, the cargo may be transferred across 
the cells to reach the underlying tissue [22].  
 
1.1.3 Fusion with endosomes and endosomal escape mechanisms 
Once the cargo is internalized following a preferential route of endocytosis, the vesicles are 
delivered to endosomes. The cargo is then either sorted back to the cell surface or transported into 
other compartments such as multivesicular bodies (MVBs) or lysosomes for degradation [18]. An 
efficient carrier should provide a mechanism to escape from endosomes, circumvent lysosomal 
degradation, and effectively transfer the DNA into the cytosol.  
Different endosomal escape mechanisms can be observed based on the type of carrier internalized 
in the cytosol. In the case of lipid-based carriers, the process of endosomal escape can occur 
through two distinct mechanisms: inverted hexagonal configuration and a flip flop model. An 
example of the first mechanism is commonly observed with the internalization of lipoplexes 
containing the neutral phospholipid dioleoyl-phosphatidylethanolamine (DOPE). DOPE has been 
reported to destabilize endosomes, causing the escape of the cargo. Precisely, DOPE can induce a 
change in the configuration of the lipoplex into an unstable inverted hexagonal configuration, 
which can rapidly fuse to anionic vesicles and release the DNA into the cytosol [23-25].  
The second mechanism of lipoplex fusion and release of DNA is explained by a “flip-flop” model. 
In this model, the release of DNA is facilitated through four sequential steps: 1) the lipoplex is 
endocytosed in the endosome membrane, 2) the membrane is destabilized by inducing the anionic 
lipids, which face the cytoplasm, to orient themselves towards the endosomal lumen known as 
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“flipping effect”; 3) the anionic lipids form a neutral net charge with the cationic lipids of the 
lipoplex, and 4) the DNA is displaced and released into the cytoplasm [26].  
Finally, in the case of polyplexes, the endosomal mechanism of escape can be explained by a 
“proton sponge” model. Polyplexes made of cationic polymers such as polyethyleneimine (PEI) 
can be easily protonated during endosome acidification due to the presence of amine groups. As a 
result, passive chloride influx causes osmotic swelling and eventually rupture of the endosome 
with subsequent release of the polyplex [8, 27]. However, the release of polyplexes into the 
cytoplasm can hinder the efficiency of the transfection, especially if the DNA cannot easily 
dissociate from the carrier. Several strategies have been proposed to enhance the dissociation of 
DNA from the polyplex. For instance, reducible Poly(l-lysine) (PLL) can be degraded once in the 
intracellular environment, and thus induce the release of DNA for subsequent gene expression 
[28]. 
 
1.1.4 Cytosol trafficking and nuclear entry 
After dissociating from the polyplexes and lipoplexes, the DNA must travel through the viscous 
and crowded cytoplasm to reach the nucleus. Small DNAs (less than 2000 bp in size) have been 
shown to diffuse in the cytoplasm, whereas larger DNA molecules are unable to diffuse and require 
active methods of transport [29]. The only possible mechanism of DNA translocation to the 
nucleus is the active transportation mediated by microtubules and molecular motors proteins 
known as dynein [30, 31]. A recent study supported this hypothesis by demonstrating that a 
decrease in gene expression is generally observed when the microtubules assembly and dynein 
activity are inhibited by the co-administration of the drug nocodazole and antibodies against 
dynein [32]. By contrast, the same study proved that the translocation of DNA into the nucleus is 
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an independent actin process since no change in gene expression was detected when actin 
polymerization was inhibited.  
Finally, the nuclear entry of plasmid DNA is regulated by a passive transport mechanism occurring 
during cell division. At this stage, the nuclear membrane is temporarily disassembled, which 
enables the DNA to enter [33]. Aside from passive transportation, several strategies have been 
investigated to enhance the nuclear entry of plasmid DNA. One of them consists of utilizing a gene 
containing a single nuclear localization signal peptide that can facilitate nuclear entry [34]. 
Similarly, specific DNA sequences can be designed to bind to transcription factors in the 
cytoplasm to form efficient protein-DNA complexes that can enter the cell nucleus by protein 
transporters [35].  
In the next section of Chapter 1, we will discuss the main viral and non-viral carriers available for 
efficient delivery of exogenous genes with an emphasis on the advantages and limitations of each 
strategy. Finally, we will highlight how the cell microenvironment and the intrinsic features of the 
cell machinery can impact the efficiency of internalization of genetic material.  
 
1.2 Carrier-based strategies for intracellular delivery: Viral vectors 
Viral vectors such as adenoviruses, adeno-associated viruses, retroviruses, and lentiviruses can be 
used as a delivery vehicle for both transient and permanent expression of specific genes in stem 
cells [36]. These vectors enable the design of specific cell-based therapies to treat a large variety 
of metabolic disorders, cardiovascular diseases, as well as different types of cancer. They can be 





1.2.1 DNA-based viruses 
Adenoviruses have been under investigation for over 20 years in many clinical trials [37]. This 
type of viruses possesses double-strand DNA in their genome with a packaging capacity of 7.5 
kbp of foreign DNA. Adenoviruses enable transient episomal expression of a target gene in a broad 
range of host cells. Since the adenovirus DNA does not integrate into the genome of the host cells, 
this type of viruses is considered to be safe. However, the first generation of these viruses has been 
shown to cause a robust immune response. Hence, implementing these viruses as viral vectors in 
gene delivery required the modification of the virus genome. This process can be achieved by the 
partial or complete deletion of the genetic information to generate the so-called “gutless” vectors 
with a packaging capacity of 30 kbp [38]. Despite the increased safety of these vectors, their use 
in gene therapy and regenerative medicine is limited. For instance, one of the main challenges still 
unresolved is their inactivation by the blood components such as proteins of the coagulation 
cascade or complement proteins when administered systemically [39].   
Another important class of DNA viral vectors is represented by adeno-associated viruses (AAV). 
AAV are single-stranded DNA viruses that possess an extremely low risk of pathogenicity because 
of their inability to integrate into the genome of the host cell. These viruses need a helper virus 
such as adenoviruses for replicating and completing their life cycle [37]. Since AAVs are stable in 
the blood, there is a limited risk of a severe systemic inflammatory response associated with the 
administration of these viruses [40]. However, one limitation of AAV is that their transfection 
efficiency decreases rapidly in dividing cells, and they are more suitable for the transfection of 





1.2.2 RNA-based viruses 
Viruses carrying RNA are also widely investigated as an important tool for the design of gene 
therapies to transfect stem cells. One example is represented by retroviruses which are capable of 
reverse transcription of their RNA into DNA. Thus, retroviruses can integrate their DNA copy into 
the genome of the host cells. Before the discovery of clustered regularly interspaced palindromic 
repeats-CRISPR associated protein 9 (CRISPR-Cas9), retroviruses represented the only possible 
strategy to modify a single gene in patients. This type of viruses can accommodate up to 8 kb of 
RNA foreign inserts, and they can induce permanent gene expression. Retroviruses have been 
successfully used to transfect stem cells, or early precursors of blood cells ex vivo to treat several 
conditions, including severe combined immunodeficiency (SCID) [40, 41]. However, the 
application of these viruses has been associated with a possible risk of oncogenesis [42]. The other 
drawback of retroviruses is that they are inefficient in infecting nondividing cells [36]. 
A more appealing alternative is represented by lentiviruses, which is one of the best options for 
therapeutic applications when a long-term expression is required. Lentiviruses belong to the family 
of retroviruses that include HIV. These viruses can infect both dividing and non-dividing cells 
with a lower risk of genotoxicity due to the absence of preferential integration in the host genome 
close to the onset of transcription units [40, 43]. Lentiviruses have been implemented in several 
clinical trials for the treatment of a variety of diseases such as X-linked adrenoleukodystrophy and 
Thalassemia major. Precisely, patients treated with hematopoietic stem cells transfected ex-vivo 
with lentiviruses showed significant improvement and decreased the need for blood transfusion 
[44]. Although successful in many applications, the possible risks of oncogenesis still remains a 
big concern for their application in the clinic.  
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Overall, viral vectors have significantly advanced the field of gene therapy in both clinical and 
non-clinical applications due to their high efficiency. However, safety concerns and limitations, 
including carcinogenesis, immunogenicity, difficulty in vector design, and restricted DNA 
packaging capacity, make them less ideal candidates for gene delivery [45-47]. For these reasons, 
non-viral vectors are an equally attractive option for gene therapy applications, and great efforts 
are directed towards the synthesis of more safe gene carriers that rely on organic or inorganic 
materials.  
 
1.3 Carrier-based methods: non-viral carriers 
Non-viral carriers can be fabricated from inorganic, or organic materials, including polymers and 
lipids. Their size, surface charge distribution, and loading efficiency can be controlled and 
customized due to the type of material used for their synthesis and process of fabrication. This 
great versatility in their design combined with their superior biological safety compared to viral 
vectors are the main reasons these carriers have been the subject of large investigation for gene-
based therapies. Non-viral carriers can find applicability for the intracellular delivery of exogenous 
genetic materials in the form of small DNA, large DNA (plasmid DNA), siRNA, and mRNA. 
Similar to viral vectors, non-viral carriers have been investigated in many clinical trials to treat a 
wide variety of diseases, including cystic fibrosis, multiple myeloma, ovarian, and bladder cancer 
[6]. The following discussion will highlight the available strategies for intracellular gene delivery 
using carrier-based methods. In particular, different classes of non-viral vectors will be discussed, 
including inorganic and organic-based nanomaterials as well as lipid and polymer-based carriers 




1.3.1 Inorganic and organic nanomaterials 
Inorganic materials such as calcium phosphate, silica, gold, and quantum dots have been widely 
investigated for the fabrication of nanocarriers with potential applications for gene delivery [48].  
The shape, porosity, size and surface charge of the inorganic nanocarriers can be precisely 
designed to prevent the degradation or denaturation of the entrapped or adsorbed payload (e.g., 
DNA and mRNA) [49]. Additionally, inorganic nanomaterials offer several advantages such as 
biocompatibility, low cytotoxicity, and ease of functionalization, which are essential 
characteristics to formulate efficient gene-based therapies [50, 51].  
For instance, the surface of gold nanoparticles can be functionalized with polar functional groups 
to enable the complexation of DNA. A possible strategy is to modify gold nanoparticles with pH-
responsive chemical groups that can allow the intracellular delivery of genetic material. 
Specifically, a pH-responsive dynamic system based on intercalated motif (i-motif) DNA was 
conjugated covalently to a surface of gold nanoparticles. The i-motif DNA was linked to a 
therapeutic siRNA for silencing the PLK1 gene, which is involved in genome stability and mitosis. 
Upon intracellular delivery, the gold particles were internalized in endosomes. The lower pH 
caused a conformational change in the structure of i-motif DNA, which led to the aggregation of 
the gold nanoparticles. This process facilitated the endosomal escape of the gold nanoparticles 
determining the release of siRNA into the cytosol [52].  
Another interesting option is represented by quantum dots (QDs), which are semiconductor nano-
meter sized (2-10 nm in diameter) particles. QDs possess many advantages, such as narrow and 
symmetric emission, strong absorption, and high photostability. Due to these distinct properties, 
QDs have been used in bioimaging, biosensing, and particularly in gene delivery applications [53-
55]. In one study, multiple QDs coated with poly(ethylenimine) (PEI) were fabricated to facilitate 
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the binding of green fluorescence protein (GFP) plasmid DNA. These complexes were effectively 
delivered into human mesenchymal stem cells (hMSCs). The results from this study demonstrated 
that PEI-coated bundled QDs nanoparticles had higher transfection efficiency when compared to 
naked QDs [56]. In another study, plasmid DNA was conjugated to QDs for long-term intracellular 
and intranuclear tracking in Chinese hamster ovary (CHO-K1) cells. Specifically, plasmid DNA 
was complexed with phospholipid-coated QDs by a peptide nucleic acid–N-succinimidyl-3-(2-
pyridylthio) propionate linker. This complex yielded 62% transfection efficiency, which was 
comparable to the control group (unconjugated plasmid DNA) [57]. Although QDs have shown 
promising potential in various applications, they can be costly to fabricate and can induce toxicity 
to cells due to the possible release of heavy metals [58].  
Calcium phosphate is another important inorganic compound that can be used to synthesize 
biocompatible nanoparticles for gene delivery. These nanomaterials, due to the presence of 
calcium, can easily establish ionic bonds with phosphate groups present in the nucleic acid 
backbone [59]. The DNA-calcium phosphate complex can be internalized across the cell 
membrane through ion channel transportation. The procedure to create a nano-complex between 
DNA and calcium phosphate is straightforward. The process consists of a simple mixture of 
calcium chloride with DNA, followed by the addition of a phosphate-buffered saline solution [60]. 
However, this conventional method for the formation of a DNA-calcium phosphate complex has 
several significant limitations such as low gene expression, insufficient endosomal escape 
mechanism, limited protection of the DNA from degradation in the cytosol, uncontrolled crystal 
growth, and finally low nuclear uptake [61, 62]. To overcome these issues, Sololova et al., added 
another layer of calcium phosphate to the DNA-calcium phosphate core complex that protected 
the DNA from degradation by lysosomes in different cell lines [63]. This additional layer also 
15 
 
prevented crystal growth by the absorption of DNA on the outer layer on the surface of calcium 
phosphate nanoparticles. Furthermore, other studies have reported how other parameters, such as 
the concentration of CaCl2 and DNA, temperature, pH value, and the time of complexation can 
modulate the efficiency of calcium phosphate-based transfection methods [64]. Although calcium 
phosphate is an effective, simple, and well-known delivery method for in vitro transfection, its 
efficacy is hampered in vivo due to their rapid aggregation and risk of precipitation [51].  
Aside from inorganic material, carbon-based nanomaterials have been explored for gene delivery. 
For example, single-walled and multi-walled carbon nanotubes (CNT) have found applications in 
this field of study owing to their special structural, mechanical, electrical, and chemical 
characteristics [65-68]. These tubes are chemically inert, and their surface can be easily 
functionalized with biological molecules such as proteins, peptides, and nucleic acids [69, 70]. 
Surface functionalization of CNTs as gene delivery vehicles can be achieved by hydrophobic or 
- interaction between the CNTs and the polar ring of the DNA backbone [71]. In one study, 
ammonium functionalized CNTs were bound to plasmid DNA by electrostatic interactions, and 
the complex was successfully internalized into HeLa cells [72]. In another investigation, the 
surface of multi-walled CNTs was modified with PEI through electrostatic interactions. This 
strategy was used to securely immobilize DNA on to the surface of CNTs by noncovalent bonding 
[73]. All these non-covalent approaches for binding DNA to CNTs have the advantage of releasing 
the DNA more favorably compared to strategies that rely on the covalent linkage of DNA. Aside 
from all the benefits that CNTs provide, there are shortcomings associated with the use of these 
carries in cells. For instance, CNTs are not degradable inside cells, and hence, they can be cytotoxic 
to them. However, the level of toxicity depends on the structure of CNTs, and it can be reduced 
by introducing water-soluble functionalities on the surface of CNTs [68, 74].  
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1.3.2 Lipid-based carriers  
Another important class of carriers for gene delivery that has been used extensively both in vitro 
and in vivo is the one derived from lipids. The physical properties of lipid-based carriers such as 
stability in solution, superficial charge, and loading efficiency strictly depend on the chemistry of 
the lipid used for their fabrication. A specific class of lipid carriers is represented by liposomes, 
which are made of phospholipids. These compounds are amphiphilic molecules composed of a 
cationic, anionic, or neutral head group and a hydrophobic tail that assemble into bilayered 
spherical structures with sizes ranging from 20 nm to a few microns [33]. Liposomes displaying a 
cationic superficial charge have been used extensively for intracellular delivery of DNA due to 
their ability to form a stable electrostatic complex with the phosphate groups of DNA [75-80]. The 
size of the lipid/DNA (lipoplex) complexes vary from 100 nm to 1 µm, which is based on the type 
of lipid structure selected to fabricate the liposomes [81]. Liposomes composition can also be 
modified by the addition of neutral lipids that facilitate the release of DNA from endosomes by 
hexagonal phase formation mechanism, as discussed in section 1.1.3 [51]. Commonly used neutral 
lipids are cholesterol, dioleoyl phosphatidylethanolamine (DOPE), and 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP) that provide the fabrication of versatile lipid-based gene 
carriers.  
The use of liposomes as gene delivery carriers offers substantial advantages compared to other 
types of vectors. Firstly, their fabrication is relatively simple, with limited costs of production. 
Secondly, they do not trigger adverse immune responses and present negligible levels of 
cytotoxicity. Moreover, they can be used to deliver large pieces of DNA, as large as chromosomes, 
and they can protect the DNA from nucleases-mediated degradation [82]. Different types of 
liposome-based gene delivery systems have shown promising results in clinical trials to treat 
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several diseases such as cystic fibrosis, advanced oral squamous cell carcinoma, solid tumors, and 
melanoma [83-86]. However, several challenges limit their efficacy in vivo, including their limited 
stability and poor transfection efficiency. These problems arise from the fact that the lipoplexes 
can be sequestered by circulating proteins in the serum, which greatly reduces their efficacy 
compared to viral vectors.  
 
1.3.3 Polymer-based carriers 
Similar to lipid-based nanomaterials, the physical and chemical properties of polymer-carriers can 
be finely controlled and modulated based on the type of polymer selected. Polymers can be of 
synthetic or natural origin; they can display a variety of chemical functionalities in their repetitive 
units and possess different molecular weights. These set of parameters can be selected to design 
polymer-carriers that have great potential for gene delivery [87].  
Ideally, the polymeric nanocarrier should establish electrostatic interaction with plasmid DNA to 
form a complex that protects the genetic material from degradation.  Additionally, the polymeric 
carrier should be stable in physiological conditions and should not promote any protein 
aggregation once administered [75]. A possible solution to this problem is the modification of the 
surface of the polymeric particles with polyethylene glycol (PEG) to create stable polymeric 
carriers that do not establish protein interactions and are characterized by limited clearance by the 
reticuloendothelial system (RES) when used in vivo [88-90]. Finally, upon internalization, the 
delivery of the genetic material to the nucleus strictly depends on the ability of the polymer carrier 
to avoid degradation of the DNA induced by lysosomes.  
Based on these criteria, several polymers have been investigated for the design of efficient 
nanocarriers for gene delivery. For instance, one of the most used polymers for this purpose is PEI 
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due to its ability to form polyplexes with DNA by establishing electrostatically interactions 
between the positively charged primary amine groups and the phosphate groups of DNA [91, 92]. 
PEI can be synthesized in a linear and a branched configuration, which displays different chemical 
properties [93]. Branched PEI is more reactive due to the presence of primary amine groups and 
can form smaller DNA/PEI polyplexes. However, linear PEI is less toxic and has a higher 
transfection efficiency [94]. Irrespective of its configuration, PEI also possesses a high pH 
buffering capacity, and it can act as a “proton sponge,” which commonly leads to the endosomal 
escape of PEI-carriers from lysosomes. Specifically, PEI-based nanocarriers once internalized 
within a lysosome (pH 4.5-5.0) can uptake protons that are pumped into this acidic intracellular 
compartment. As a result, passive diffusion of chloride ions occurs within the vesicle leading to 
water influx. Finally, due to the increased osmotic swelling, the endosome ruptures and the PEI-
DNA complex is released into the cytoplasm  [95]. This proton sponge hypothesis enables PEI-
based nanocarriers to escape from lysosomes avoiding the degradation caused by them. Similarly, 
the same pH buffer capacity of PEI is responsible for the inhibition of lysosomal nucleases, which 
are the main enzymes responsible for the cleavage of phosphodiester bonds of DNA [95]. Despite 
all these advantages, one of the challenges associated with the use of PEI-based carriers is their 
low transfection efficiency and cytotoxicity induced by the presence of numerous positive charges 
[96]. A possible strategy adopted to reduce the cytotoxicity of PEI is to coat the PEI/DNA polyplex 
with disulfide-modified hyaluronic acid (HA-SS-COOH). This modification has been shown to 
promote higher cell viability combined with a 14-fold increase in transfection efficiency compared 
to PEI/DNA without any modification [97].  
Another example of cationic polymer widely used in gene delivery application is poly-L-lysine 
(PLL) that has the advantage of being biodegradable when used for in vivo applications. PLL has 
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been tested for pancreatic cancer treatment and hormone stimulation in melanoma cells [98, 99]. 
Similar to PEI, PLL can form electrostatic complexes with plasmid DNA or RNA efficiently. 
However, PLL has a relatively lower transfection efficiency compared to PEI [100]. One solution 
to this problem is the design of particles consisting of PLL conjugated with targeting moieties of 
endosomolytic agents such as fusogenic peptides that can promote endosomal escape and prevent 
DNA degradation [101]. Additionally, to overcome lysosomal degradation, PLL has been 
modified with histidine residues, and the transfection efficiency of histidylated PLL was 3-4.5 
orders of magnitude when compared to PLL alone [102].  
 
1.4 Strategies to enhance gene delivery by modifying the cell microenvironment 
As described earlier, the intracellular delivery of genetic material can be controlled by the proper 
selection of a specific carrier. However, the biological and physical cues that define the cellular 
microenvironment have a similar impact on the delivery efficiency and corresponding transfection. 
Precisely, cells actively interact with the extracellular environment by sensing physical, biological, 
and mechanical stimuli. Cells respond to these cues by converting them into intracellular signaling 
cascade that commonly leads to significant changes in cell morphology, proliferation, and 
expression of key proteins [103, 104]. Understanding the role of these cues can be useful to 
augment the efficacy of gene-based strategies. In this section, we will examine the possible 
chemical and physical approaches that have been explored so far to modify the cell-substrate and 






1.4.1 Chemical modification of the substrate to enhance gene delivery to adhering cells 
The cell microenvironment directly controls various cellular responses such as morphology, 
adhesion, and proliferation. Precisely, cells adhere to a substrate by establishing focal adhesions 
through the presence of specific transmembrane receptors called integrins that recognize specific 
domains of the proteins of the extracellular matrix (ECM). The extent of these anchorage points 
and the corresponding rearrangement in the cellular cytoskeleton can directly impact gene delivery 
and transfection efficiency [105].   
One of the avenues explored to enhance the internalization of genetic cargo is by controlling the 
formation of anchorage points on a cell-substrate. For instance, several proteins present in the 
ECM, including fibronectin, laminin, collagen I/IV, and vitronectin, can be adsorbed as coatings 
on the surface of synthetic substrates to enhance gene transfection [105]. Dhaliwal et al. examined 
and compared the effect of collagen I and fibronectin coatings on the transfection efficiency of 
bone marrow-derived mesenchymal stem cells (MSCs) using PEI as a non-viral vector. Cells 
cultured on fibronectin-coated substrates exhibited higher transfection, although higher 
internalization of PEI/DNA polyplexes was observed for the collagen I group [106].  
Based on these results, the same authors investigated in another study the role of Rho-GTPases 
activity in mouse mesenchymal stem cells seeded on the same types of substrates. Rho-GTPase 
proteins are involved in the modulation of cytoskeletal dynamics, including cellular contractility 
and stress fiber formation. Stem cells cultured on fibronectin-coated substrates expressed higher 
amount of Rac1, cdc42, and RhoA compared to the cells cultured on collagen I. Additionally, after 
inhibition of these regulators a decrease in transfection efficiency was observed suggesting that 
actin stress fiber formation is the main responsible for intracellular trafficking. Overall, these 
results indicated that transfection of stem cells seeded on fibronectin-coated substrates is directly 
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controlled by integrin binding, cytoskeletal dynamics (stress fibers), and RhoGTPases activity 
[107].  
Polysaccharides found in the ECM can also be used to modulate the cytoskeletal rearrangement 
and influence intracellular gene delivery. For example, hyaluronic acid (HA) is a high molecular 
weight polysaccharide found in soft connective tissues that can be conjugated with other polymers. 
These conjugates can be implemented as interactive coatings that can affect the cellular 
morphology and modulate the delivery of genes.  In one study, murine adipose-derived adult stem 
cells were cultured on glass slides coated with chitosan and chitosan modified with HA. Cells were 
subsequently transfected with naked DNA, and the level of transfection efficiency was compared 
to cells seeded on tissue culture plates without any coating. Cells seeded on chitosan and chitosan-
HA coated surfaces formed spheroids and displayed a higher transfection efficiency. The change 
in cytoskeletal rearrangement was associated with an upregulation of RhoA gene, which controls 
the assembly of focal adhesions and actin stress fibers [108]. Upregulation of RhoA could be the 
reason for the increased endocytosis, and higher internalization of the plasmid DNA observed in 
the cells cultured on chitosan and chitosan-HA groups [109].  
Aside from natural polymers, synthetic coatings can be used to bind proteins and regulate change 
in cell morphology for efficient intracellular delivery. Specifically, polymeric self-assembled 
monolayers (SAMs) can be homogenously manufactured and subsequently added to the substrate 
to allow protein and cell adhesion [110]. For example, gold substrates have been coated with 
different SAMs displaying methyl or carboxyl groups. NIH-3T3 fibroblasts were seeded on these 
coated substrates, and the cells were transfected with GFP plasmid using Lipofectamine2000 and 
branched PEI. Irrespective of the carrier used, higher transfection efficiency was observed for the 
fibroblasts seeded on the substrate coated with SAMs modified with carboxylic groups [111].  
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Another interesting alternative to enhance gene delivery is known as substrate-mediated gene 
delivery. This strategy consists of  immobilizing  naked or complexed nucleic acids on a substrate 
so that the cargo is available for cellular uptake after seeding [112]. This process is also known as 
“reverse transfection”, which is accomplished by electrostatically or covalently immobilizing 
DNA onto substrates [113-115]. In one study, tissue culture well plates were coated with different 
serum and ECM proteins, including bovine serum albumin (BSA), fetal bovine serum (FBS), 
fibronectin, collagen I, and laminin. Subsequently, branched PEI/DNA complexes were 
electrostatically adsorbed on the protein-coated substrate to facilitate gene uptake by NIH-3T3 
cells [116]. The lipoplexes uptake was significantly higher on the substrate coated with fibronectin 
and collagen I. However, the transfection efficiency was significantly enhanced in the fibronectin 
group compared to all the other protein coatings. It was concluded that the augmented cellular 
focal adhesion expression and cytoskeletal rearrangement induced by the presence of fibronectin 
was the main reason for the increased endocytosis and intracellular trafficking of the immobilized 
lipoplexes.  
 
1.4.2 Physical modification of the cell-substrate to enhance gene delivery to adhering cells 
Aside from the chemical modification of the cell-substrate, cellular responses can be controlled by 
altering the physical properties of the microenvironment [117, 118]. Several studies have shown 
that a change in topography or stiffness of the substrate can directly affect cell adhesion, 
proliferation, focal adhesion expression, and cytoskeletal dynamics, which in turn can enhance 
transfection efficiency using different non-viral carriers [119-121].  
The topography of a cell-substrate can be designed to mimic the physical cues found in the ECM. 
Different structures, including grooves, pores, fibers, and pillars, can be fabricated using 
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lithography, nanoimprinting, and acid etching using a variety of synthetic substrates [122, 123]. 
For instance, the topographical properties of silicon substrates can be modified by introducing 
micropillars, nanopillars, or grates made of poly(methylmethacrylate) (PMMA). In a study by Teo 
et al., silicon-PMMA substrates displaying micro and nanopillars have been tested on different 
cell lines, including mesenchymal stem cells, breast cancer cells, and simian fibroblasts. The 
change in morphology observed in all the different cell lines seeded on the substrates modified 
with micro and nanopillars was associated with a higher transfection of GFP-encoding 
DNA/Lipofectamine2000 complex when compared to the cells seeded on the flat substrates used 
as a control. It is likely that the changes in cytoskeletal rearrangement induced by the different 
topographies indirectly enhanced  the process of  endocytosis in the tested cells [124].  
Based on a similar concept, another research group investigated the transfectability of naked 
plasmid DNA in hMSCs seeded on negatively charged polyurethane (PU) substrates containing 
microgrooves [125]. The transfection efficiency of hMSCs seeded on the modified substrates by 
using naked GFP plasmid DNA was similar to the cells transfected with standard transfection 
reagents. hMSCs seeded on the PU substrates containing the microgrooves also displayed an 
increase in the expression of integrins β1 and α5, as well as focal adhesion kinases (FAK). Overall, 
all of these factors may have contributed to the observed enhancement of endocytosis and 
intracellular trafficking of plasmid/DNA complexes. 
Apart from substrate topography, another physical parameter widely investigated to modulate gene 
delivery is the stiffness of the cell-substrate. Different biomaterials can be engineered to create 
biomimetic substrates with values of stiffness ranging from 103 Pa to 109 Pa, which are 
characteristic of  soft and hard tissues, respectively [113]. The elastic modulus of the cell-substrate 
is one of the main modulators of cell spreading, cell signaling, and stem cell differentiation [126-
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128]. Additionally, cell membrane tension, actin fiber formation, and cell area can be significantly 
modified by the stiffness of the substrate. Interestingly, these changes have been shown to 
modulate the internalization of bio-conjugated nanoparticles and non-viral vectors, as well as 
transgene expression [129, 130]. In a study conducted by Jong et al., the effect of substrate stiffness 
on transfection efficiency of murine MC3T3-E1 pre-osteoblasts using PEI-DNA was investigated. 
In this work, the stiffness of alginate-based hydrogels was varied from 20 kPa to 110 kPa and used 
as a model to study transfection efficiency. Cells seeded on the stiffer substrates showed higher 
proliferation, cell survival, and transfection [131]. A similar increasing trend for internalization 
and transfection of linear PEI-DNA was observed when NIH-3T3 fibroblast, myoblast, and bone 
marrow stromal cells were seeded on fibronectin-conjugated poly(ethylene glycol) diacrylate 
hydrogels with varying stiffness from 10 to 670 kPa. Additionally, the stiffness of these hydrogels 
affected the cell’s projected area as well as the nuclear aspect ratio. These results suggest that actin 
stress fibers and microtubules rearrangement are responsible for the observed changes in cellular 
morphology and nuclear shape. These cytoskeletal components directly influenced the intracellular 
trafficking of polyplexes and as a result, the transfection efficiency [132]. 
 
1.5 Intracellular delivery by membrane disruption methods 
Internalization of extracellular cargo has been investigated through alternative approaches that do 
not require the use of any carrier. These methods aim to increase the permeability of the cell 
membrane by creating transient pores, lesions, or defects of different shapes and sizes. Although 
these methods overcome the possible cytotoxic effects and safety concerns associated with the use 
of any nanomaterial or viral vector, several parameters need to be considered to guarantee efficient 
delivery without affecting the cell viability. One of the big challenges is that the method used to 
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create the pores should not be toxic and should not induce irreversible damage to the cell 
membrane. Similarly, several of the approaches are not efficient enough because of the limited 
number of cells that can be processed (low throughput), thus limiting their applicability in pre-
clinical and clinical applications.  
Overall, these methods can be subdivided into two major classes: direct penetration and 
permeabilization-based approaches (Figure 1.3). 
 The first class consists of a group of strategies aimed to deliver cargo directly into the intracellular 
space by utilizing a vehicle or a conduit that pass through the cell membrane. In this category, it 
is possible to include microinjection, ballistic particles, and nanoneedles-based delivery. The 
 
Figure 1.3 Strategies for the permeabilization of the cell membrane using physical and 
mechanical approaches. A) Nanostraws induce membrane disruption for the delivery of 
extracellular cargo. B) and C) Electroporation strategies for the delivery of external cargo. D) 
Conventional heating induces changes in the permeability of the cell membrane. E) Heat can 
be directed in localized regions of the cell membrane to reduce the risk of toxic effects. F) Cell 
squeezing through micro-constrictions induces the formation of transient pores in the cell 




second category, such as permeabilization-based strategies, enables the delivery of extracellular 
cargo primarily by generating pores in the cell membrane. These pores can be created by different 
physical and mechanical methods that will be described more in detail in the following sections  
 
1.5.1 Penetration methods: microinjection, nanoneedles, and biolistic-based delivery 
Microinjection is the first method of intracellular delivery that was the first to be used in 1911 and 
perhaps the most direct method for delivering exogenous materials regardless of the cell type 
[133]. The materials are directly injected into the cells by using fine glass needles [134]. Different 
types of molecules, including DNA, RNA interference, proteins, peptides, and non-diffusible 
drugs, can be delivered into cells with nearly 100% efficiency [135-139]. Furthermore, precise 
control over the volume of the cargo delivered into the cytoplasm or the nucleus can be achieved 
by microinjection. Despite its accuracy and versatility, microinjection suffers from being a low 
throughput and time-consuming method of delivery [140, 141]. Additionally, utilizing 
microinjection in small cells such as blood cells (< 10 µm in diameter) can be challenging. It 
should also be noted that using microinjection in non-adherent cells can add more complexity to 
the overall process as there is the need for extra equipment to keep the cells in place prior to being 
microinjected [142]. 
Similar to microinjection, nanoneedles are nano-scaled features that can penetrate into cells and 
deliver exogenous cargos directly in the cytosol. The cargo can be delivered by using nanoneedles 
in three different ways. In the first method, the target material is attached on the nanoneedles and 
subsequently dissociated form them upon entering the cytosol. Different types of molecules, 
including siRNA, DNA, proteins, and peptides, have been successfully delivered in several cell 
lines such as neurons and immune cells [143-145]. Another possibility consists of directly 
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pumping the cargo into the cytoplasm via hollow nanoneedles or “nanostraw”. The advantage of 
using this method is the temporal control over the concentration and volume delivered [146]. 
Finally, in the third strategy, a grid of diamond nanoneedles is placed on top of adherent cells and 
subsequently spun down to create small holes in the plasma membrane, thus allowing the diffusion 
of the delivered materials. This approach has been successfully used to deliver different types of 
molecules into primary neurons while maintaining high cell viability [147]. Overall, nanoneedle 
injection is a straightforward and efficient approach, although its applicability is limited by the 
difficulty associated with the fabrication of the nanostructures and their utilization at large scales. 
Biolistics-based intracellular delivery, also known as “gene gun”, utilizes high-velocity 
microprojectiles to deliver DNA and other types of molecules into different cell types. The 
microprojectiles need to reach an optimum velocity to be effective. This requirement can be 
provided by a gas shock wave in the form of a high-voltage electronic discharge, chemical 
explosion, or helium shock [148, 149]. The particles (tungsten, gold, or silver) will then strike the 
cell membrane, entering the cytosol, and release the cargo molecule from the surface into the 
cytoplasm. The size of the particles conjugated with the delivery material should not exceed one-
tenth of the size of the target cells. DNA, mRNA, siRNA, and proteins have been successfully 
delivered using this method in mammalian cells [150-152]. One of the limitations of this method 
is the inherent inconsistency of delivery. Specifically, the particles are bombarded on to the 
cultured cells from a distance that can vary from one experiment to another. Also, another major 
disadvantage of this method is the cytotoxicity that the particle can cause when impacting the cell 





1.5.2 Permeabilization methods by using energy sources 
Permeabilization methods can generate transient pores in the cell membrane by using different 
types of energy source, including electrical, thermal, and ultrasounds. For instance, electroporation 
is a very useful method that relies on the use of rapid high-voltage electric pulses to generate an 
electric field higher than the capacitance of the cell membrane leading to the formation of 
reversible pores [139]. As a result, extracellular molecules enter the cytosol by passive diffusion 
or electrophoretic force. Electroporation has been around since the1980s and has been successful 
in the intracellular delivery of plasmid DNAs, mRNA, proteins, quantum dots, antibodies, and 
many other cargos [153-157]. However, the strong, intense electrical fields required to deliver 
large bioactive molecules such as proteins and DNA can cause significant damage or cell death 
[158, 159]. Different strategies have been recently implemented to reduce the adverse effect of 
high voltage in conventional electroporation. Specifically, microfluidic devices have been 
designed to provide a localized electrical filed to a single cell, thus reducing the required voltage 
by 100-fold. Another advantage of coupling electroporation with microfluidic chips is the 
possibility to design systems that can expose cells to high voltages while keeping them at a larger 
distance from the electrodes [160]. 
Aside from electrical pulses, membrane disruption and small holes can be created in the cell 
membrane by different types of thermal treatment. For instance, it is possible to cause lipid 
dissociation in the plasma membrane when the cells are exposed at supraphysiological 
temperatures higher than 42° C. This effect is mainly due to the high kinetic energy, which causes 
intense molecular fluctuations. Specifically, it has been proved that small molecules (< 1 kDa) can 
be internalized into 3T3 fibroblasts at temperatures above 55° C [161].  
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On the contrary, at temperatures below 0° C ice crystals start to form. Upon thawing, the ice 
crystals can cause cytosolic expansion, which triggers the formation of holes in the membrane. 
Finally, rapid heating between physiological temperatures (0° C- 42° C) can generate small 
transient holes in the membrane [162]. However, these bulk thermal induction methods can be 
harmful and hinder cell functionality. One way to avoid these detrimental effects is to confine the 
heat energy to a localized area by using thermal inkjet printers. Successful gene transfection in 
Chinese hamster ovary (CHO) cells was observed by using this technology [163]. Another strategy 
to circumvent the detrimental effect of bulk thermal induction to cells is to use absorbent 
nanoparticles, which can serve as nucleation sites for intense localized heating upon laser 
irradiation [164]. 
An alternative type of energy that can be used to create temporary holes in the cell membrane is 
the one provided by ultrasounds. This method is generally known as sonoporation.  Cells are bound 
to vibrate at a constant frequency by continuous ultrasound waves creating gas bubbles form in 
the liquid, which boosts the permeability of the cell membrane [165]. The limitation associated 
with this method is the need for powerful ultrasound pulses to promote high internalization 
efficiency. This exposure to ultrasounds waves can cause extensive plasma membrane damage and 
cell death. The observed poor cell viability is due to harsh heterogenous cavitation that causes 
damage to some cells while others remain intact [166]. To avoid cell death, targeted cavitation is 
more favorable. In this technique, cavitation bubbles are precisely positioned at a certain distance 
from the cell, which can induce a shear force required for the plasma membrane rupture [167, 168]. 
A more sophisticated and extremely high throughput (100,000 cells per minute) design has been 
developed to create membrane pores. In this platform, the cells are allowed to adhere to a porous 
substrate lined with titanium absorbers. Rapid pulse laser scanning creates cavitation bubbles 
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underneath the cells at the titanium linings inducing plasma membrane pores. As a result, large 
cargoes such as bacteria (>1 µm) can enter the cytoplasm of different types of cells [169]. 
 
1.5.3 Permeabilization by mechanical forces: “cell squeezing” 
Cell squeezing strategy has been recently proposed to generate small transient holes in the plasma 
membrane (Figure 1.4).  
 
Precisely, induction of pores is accomplished by squeezing the cells through micron-sized 
microfluidic constrictions of around half to one-third of the cell’s diameter [170-172]. This 
mechanical deformation of the plasma membrane allows the internalization of extracellular 
materials into the cytoplasm by passive diffusion without the need for a toxic carrier [173]. 
Microfluidic chips can be designed with different features and sizes to control cell squeezing. 
Precisely, the type of geometry has been shown to affect the internalization efficiency and cell 
 
Figure 1.4 Example of the cell squeezing method to create transient pores for the delivery of 





viability of extracellular cargo via the shear stress experienced by the cells [174]. Furthermore, 
this method does not induce toxicity or cell death as the plasma membrane recovers after it ruptures 
through squeezing [175]. Additionally, this technique offers the advantage of being rapid and high 
throughput without the requirement of a costly apparatus or external source of energy. The driving 
force needed for the cell’s membrane disruption can be supplied by the flow of the cell suspension 
passing forcibly through the microfluidic device [176]. Internalization of numerous types of cargos 
in many cell types has been reported by cell squeezing. For instance, several studies have 
demonstrated the possibility to successfully delivery many types of cargos such as gold 
nanoparticles, quantum dots, carbon nanotubes, and antibodies into HeLa cells [177]. More 
importantly, the cell squeezing platform can be implemented to achieve high efficiency in gene 
delivery and gene editing applications, especially in hard-to-transfect cells. Han et al. showed 
successful applicability of cell squeezing for CRISPR (clustered regularly interspaced short 
palindromic repeats)–Cas9 (CRISPR-associated) genome editing, by implementing a series of 
microfluidic devices with different geometries [178]. Single guided RNA and Cas9 protein were 
delivered in HeLa and human luminal-like MCF7 cells for inducing the mutation of specific genes 
and knocking down their functionality. Additionally, GFP plasmid was delivered with high 
efficiency in basal-like SUM 159 breast cancer cells, human SU-DHL-1 anaplastic large cell 
lymphoma cells, and mouse AB2.2 embryonic stem cells, which are known to be hard-to-transfect 
cells. In another study conducted by Ding et al., the microfluidic cell squeezing platform was 
combined with microelectrodes [179]. This unique device enhances the efficiency of delivery 
through two steps without compromising cell viability. In the first step, the cells are squeezed, and 
as a result, the membrane pores are generated, allowing the internalization of cargo molecules. In 
the second phase, the cells are passed through an electric field, which leads to disruption of the 
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nuclear envelope. Subsequently, plasmid DNA molecules can be rapidly translocated to the 
nucleus and hence increase the transfection efficiency. It has been shown that 80% expression of 
GFP plasmid took place within the first four hours of transfection, similar to microinjection. 
Overall, delivering different kinds of cargos by cell squeezing platform is rapid (millions of cells 
per seconds), safe (high cell viability), efficient, versatile, and applicable to numerous cell types. 
However, it should be noted that the correlation between cell size and delivery efficiency should 
be carefully considered when designing cell squeezing devices. For instance, if the squeezing gap 
is not optimized based on the diameter of the cells, large cells such as multinucleated cells may be 
lysed while smaller cells may not sufficiently deformed [176].  
 
1.6 Aim of the thesis  
The work that will be described in the next chapters of this thesis can be subdivided into two 
separate aims based on the strategy adopted for the intracellular delivery of the extracellular cargo.  
The first aim was to investigate the modulatory role of substrate stiffness in the transfection of 
stem cells by using conventional lipid-based carriers transporting plasmid DNA (lipoplexes).  
Chapter 2. discusses the strategy proposed to achieve this goal. Specifically, human adipose-
derived stem cells were used as a model cell line for this study and seeded on silicon-based 
hydrogels displaying different values of stiffness ranging from soft 0.5 kPa to stiff 32 kPa. The 
chapter describes how this change in this physical parameter could influence cell morphology, 
cytoskeletal rearrangement, and focal adhesion expression. Subsequently, the study focused on 
verifying whether these changes had any significant impact on the process of transfection by using 
Lipofectamine2000 complexed with plasmid DNA encoded for vascular endothelial growth factor. 
The chapter also discusses the type of endocytosis pathways activated during the internalization 
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of the lipoplexes and how a change in substrate stiffness can control the upregulation of clathrin 
and caveolin genes. The findings of this chapter are essential to advance the understanding of how 
the physical properties of the cell microenvironment can be modified to enhance the efficacy of 
lipid-based strategies for gene delivery. 
Subsequently, the second part of the thesis was focused on the investigation of a free-carrier based 
approach. Specifically, the goal was to enable the delivery of small polar molecule that cannot pass 
through the membrane such as trehalose to promote efficient cryopreservation of stem cells 
without the use of dimethylsulfoxide (DMSO). Trehalose is a cryoprotecting agent (CPA) that 
could be used as a replacement of the more toxic molecule DMSO. However, the poor permeability 
of trehalose through cell membranes limits its applicability as a CPA for stem cell banking 
application. 
Chapter 3 addresses the first part of this aim by describing the process of fabrication of a 
microfluidic chip used to squeeze the cells and create transient small pores in the cellular 
membrane to enable the delivery of extracellular cargo without the use of any carrier. The design 
of the micro-constrictions has been varied to promote maximum delivery efficiency of fluorescent 
extracellular cargo. Additionally, several parameters, including  flow rate, the gap between the 
micro-constrictions, and molecular weight of the cargo delivered, have been optimized and tested 
by evaluating cell viability. The safety and efficacy of the microfluidic device have been assessed 
by studying apoptosis and evaluation of stemness gene expression. The chapter also describes the 
mechanism involved during the process of membrane sealing after the disruption of the membrane 
induced by the microfluidic device. 
Chapter 4 presents the use of the optimized microfluidic system for the intracellular delivery of 
trehalose. The optimal concentration of trehalose both at the intracellular and extracellular levels 
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were optimized based on the cell viability assessed after cryopreservation. Additionally, several 
other biological parameters, including proliferation rate, cell morphology, apoptosis, and 
differentiation potential of  hASCs loaded with trehalose, were compared to cells cryopreserved 
using DMSO. Overall, the strategy investigated in this study is an example of a carrier-free strategy 
that can be implemented to provide the delivery of trehalose and promote a safer alternative for 
cryopreservation with respect to DMSO. 
Finally, Chapter 5 contains the concluding statements of this thesis and a summary of the key 
findings for each aim. Moreover, a discussion will be provided on how the results of this thesis  
can be used to support future developments in the field of gene therapy and stem cell banking 



















CHAPTER 2. Deciphering the role of substrate stiffness on stem cell 




Substrate stiffness is an important parameter regulating stem cell morphology and cytoskeletal 
organization. It may also play a critical role in the internalization of lipid-based nanocarriers for 
gene delivery. Based on this hypothesis, the present study investigates the role of substrate stiffness 
on non-viral transfection of human adipose-derived stem cells (hASCs) with the aim to maximize 
hASCs expression of vascular endothelial growth factor (VEGF) and enhance their wound healing 
potential. hASCs display more actin stress fibers when cultured on stiffer silicone substrates that 
mimicked the elasticity of hard tissues such as bone. This change in cytoskeletal composition 
facilitates a greater internalization of plasmid/Lipofectamine lipoplexes. Additionally, the 
investigation of the main pathways involved in endocytosis is reported by studying the gene 
expression post-transfection. Caveolin-mediated genes are upregulated in the hASCs cultured on 
the stiffer silicone substrates, thus confirming the role of actin as a key mediator in the 
internalization of lipoplexes. Transfected hASCs seeded on more rigid substrates exhibit higher 
levels of VEGF expression when compared to hASCs cultured on softer hydrogels. Overall, these 
findings suggest that a higher plasmid internalization and corresponding VEGF expression can be 
obtained when hASCs are cultured on hydrogels resembling the elasticity of hard tissues.  
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Gene delivery to stem cells is carried out using both viral and non-viral nanocarriers, which are 
designed to improve the internalization of plasmid DNA vectors encoding therapeutic genes [180, 
181]. Viral carriers, such as adenoviruses, lentivirus, and retrovirus yield a high transfection 
efficiency because the transduction of viral DNA is facilitated by the viral envelopes surrounding 
their capsids. However, several safety concerns limit their applicability in gene therapy, including 
biosafety, immunogenicity, and possibility of mutagenesis [182]. On the contrary, non-viral gene 
nanocarriers such as cationic polymers, lipids, and peptide conjugates provide a safer alternative 
to viral carriers given their low toxicity, lack of pathogenicity, versatile surface chemistry, and 
controllable size [8, 183]. These set of unique advantages makes this type of nanocarriers a suitable 
candidate to ensure enhanced DNA delivery with limited cytotoxic effects. The selected carrier 
can also have a positive impact on transfection efficiency by promoting transmembrane diffusion 
of the genetic material, circumventing lysosomal degradation of the complex, and enhancing 
intracellular translocation to the nucleus [106]. For all these reasons, the selection of an appropriate 
nanocarrier directly influences the final outcome of gene-based therapies aimed to regulate 
transient growth factor expression in stem cells.  
Aside from these carrier properties, internalization of plasmid-DNA lipoplexes is also dependent 
on the elasticity of the cellular microenvironment, which controls the cell membrane tension and 
the cytoskeletal remodeling [184]. Plasmid-DNA lipoplexes are internalized through several 
pathways including macropinocytosis, caveolin-mediated endocytosis [185], and clathrin-
mediated endocytosis [13, 186], which in turn are regulated by the polymerization of actin stress 
fibers in the cytoskeleton [187]. Therefore, understanding the influence of substrate stiffness in 
modifying the intracellular organization of actin stress fibers is beneficial in optimizing 
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transfection efficiency in non-viral gene delivery. For instance, culturing pre-osteoblasts on stiff 
substrates, which mimic the elasticity of hard tissues, has been found to enhance non-viral 
transfection efficiency [188].  
Based on this concept, we evaluated the role of substrate stiffness as a parameter in gene 
transfection of hASCs with the goal of maximizing the transient expression of VEFG-A. hASCs 
were chosen as a model stem cell line due to their high proliferative potential, ease of harvest, and 
inherent ability to produce angiogenic growth factors. hASCs were purchased from RoosterBio 
and harvested from human lipoaspirate of female donors (31-45 years old). Our hypothesis is that 
transfection efficiency and corresponding growth factor production of hASCs can be enhanced by 
varying the physical properties of the cell-substrate. Overall, our findings can be beneficial for the 
design of scaffolds with suitable stiffness for optimal transfection efficiency. Finally, this study 
will provide useful insights regarding the role of actin fiber stress as one of the main regulators of 
plasmid DNA internalization. 
 
2.2 Materials and Method 
 
2.2.1 Silicon gel substrates coating 
CytoSoft® 6-well plates presenting different stiffness (0.5 and 32 kPa) were purchased from 
Advanced BioMatrix (Carlsbad, CA, USA). The well plates were made of silicon-based gels 
displaying on the surface anhydride functional groups that can be used to covalently bind ECM 
proteins necessary for promoting cellular adhesion. The surface of the gels was pre-coated with a 
sterile solution of Gelatin type A (1% w/v) from porcine skin (Sigma-Aldrich, USA) in PBS at pH 
7.4. The coating step was carried out by adding 4 mL of gelatin solution in each well for 4 hours 
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at room temperature to ensure the homogeneous coating of the hydrophobic surfaces. The same 
procedure was applied to coat the CytoSoft® Imaging wells 24-well plates (Advanced BioMatrix, 
San Diego, CA) having different stiffness (0.5 and 32 kPa). This type of well plate was used for 
imaging cells at higher magnification (40X).  
 
2.2.2 hASCs culture and fluorescence immunostaining   
hASCs were purchased from RoosterBio (RoosterBio, USA).  Passages 4–6 were used for all the 
studies. Cells were cultured in Minimum Essential Medium Alpha Modification (α-MEM) 
(Thermo-Fisher Scientific, USA) supplemented with 15% fetal bovine serum (FBS) (Thermo-
Fisher Scientific, USA) and 1% penicillin/streptomycin (Thermo-Fisher Scientific, USA) at 37 °C 
and 5% CO2. Cells were seeded (2 × 10
4 cells/well) on CytoSoft® Imaging wells with different 
stiffness (0.5 and 32 kPa) to study the influence of substrate stiffness on the focal adhesion 
expression of hASCs. After 24 hours, the media was replaced with α-MEM without FBS, and cells 
were cultured in these conditions for 48 hours. Cells were then fixed with 4% paraformaldehyde 
for 5 minutes at 37 ⁰C followed by permeabilization with 0.1 % Triton-X100 for 10 minutes at 
room temperature. Normal goat serum (5%) was applied for 45 minutes at room temperature to 
block the samples. Mouse anti-human Paxillin antibody (1:400 with 1% goat serum, Invitrogen, 
USA) was added to cells and incubated overnight at 4 °C. Next, goat anti-mouse AlexaFluor 594 
(Invitrogen USA) (1:500 in 1% goat serum) was added to the cells for one hour at room 
temperature. Nuclei and F-actin were counterstained using Diamidino-2-phenylindole dilactate 
(DAPI, Invitrogen, USA) and phalloidin-AlexaFluor 488 (Invitrogen, USA), respectively. 
Immunofluorescence images were taken by EVOS cell imaging system (Thermo-Fisher Scientific, 
USA) and further analyzed in ImageJ for quantification of area occupied by each cell, number of 
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actin fibers, and the total area of adhesion sites. Specifically, the cell area was quantified using 7 
to 10 cells per image for a total of 10 images per group (n=10). The number of actin stress fibers 
was counted based on a total of 7 images, each containing one cell captured at 40 X magnification 
(n=7). Paxillin area was measured using 7 different images per group (n=7) captured at 40X 
magnification. A single cell in each image was analyzed for paxillin area quantification.  
 
2.2.3 Traction force microscopy 
Cell traction was calculated using constrained Fourier transform traction microscopy (FTTM) 
[189]. 0.2 µm amino-modified fluorescence microbeads were conjugated to the substrates due to 
the presence of anhydride groups on the substrates’ surface. hASCs (2 × 103/well) were seeded on 
substrates of varying stiffness and containing microbeads and allowed to grow for 24 hours. 
Fluorescence images of the microbeads were taken before and after cell detachment from the 
substrates by trypsinization. The corresponding displacement field was calculated using a 
customized Matlab code. The traction force was calculated based on the displacement field 
computed from 7 images for each group (n=7). A single cell in each image was analyzed for 
traction forces measurements. 
 
2.2.4 Plasmid construct design 
The pscAAV-GFP vector (John T. Gray, Addgene plasmid #32396) harboring the enhanced green 
fluorescent protein (EGFP) gene was digested with BamHI and NotI restriction enzymes (New 
England BioLabs, Ipswich, MA) to excise the EGFP gene. The pCMV6-XL5 mammalian 
expression vector (Origene Technologies, Rockville, MD) was digested with BamHI and NotI 
enzymes, and after purification, the linearized EGFP gene was ligated with the pCMV6-XL5 
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expression vector using T4 DNA Ligase (Promega). The resulting construct, pCMV-GFP, was 
transformed in chemically competent DH5α Escherichia coli (Invitrogen, Carlsbad, CA) to 
amplify the plasmid. Additionally, the expression vector for the human VEGF-165 gene, pCMV6-
XL5-VEGF (Origene Technologies, Rockville, MD), was also amplified by the transformation of 
DH5α E. coli. Both plasmids were extracted and purified using QIAPrep Spin Midiprep kits 
(QIAGEN Inc., Germantown, MD). 
 
2.2.5 Lipofectamine-plasmid DNA complex formation and characterization 
Prior to transfection, both plasmid DNA and Lipofectamine2000 (Invitrogen, Carlsbad, CA) were 
diluted in 150 µL of incomplete α-MEM media. Specifically, the lipoplexes were prepared by 
mixing the two components in equal volumes (150 µL) containing a 1:3 ratio of plasmid DNA (4 
μg) to Lipofectamine2000 (12 μL). The complexes were then incubated for 20 minutes at room 
temperature before addition to hASCs. The hydrodynamic diameter and the zeta potential of the 
Lipofectamine2000 and the lipoplexes were obtained using a ZetaPALS zeta potential analyzer 
(Brookhaven Instruments Corporation). Samples for DLS analysis were prepared by diluting 
Lipofectamine2000 and the lipoplexes in Opti-MEM (Thermo-Fisher Scientific, USA). On the 
contrary, zeta potential measurements were carried out by diluting the samples in KCl 1mM. 
 
2.2.6 Transfection of hASCs 
 hASCs were seeded on the different silicone substrates (105 cells/well) and allowed to proliferate 
for 24 hours prior to transfection. hASCs were cultured in complete α-MEM (15% FBS and 1% 
penicillin/streptomycin) at 37 °C and 5% CO2. The growth medium was replaced with fresh α-
MEM (2 mL/well) without FBS, and the complexes of Lipofectamine2000 and plasmid DNA (300 
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µL/well) were added dropwise to the cells (80-90% confluency). After incubation for 1 and 4 hours 
at 37°C, the media containing the complexes was removed and replaced with complete α-MEM. 
Cells were cultured for 72 hours prior to changing the media, and further analysis was conducted 
to evaluate the quantity of VEGF secreted by the cells.  
Similarly, GFP transfection of hASCs was carried out using Lipofectamine2000 according to the 
conditions reported above. Cells were cultured for 24 hours prior to fluorescence-activated cell 
sorting (FACS) analysis. Briefly, cells were trypsinized 24 hours post-transfection and 
suspended in PBS at the cell density of 1×105 cells/mL. The percentage of GFP positive hASCs 
and corresponding mean fluorescence intensity (MFI) values were determined using the Attune 
NxT flow cytometer (Thermo-Fischer Scientific, USA). Three different samples per group were 
analyzed, and the results were reported as mean ± deviation standard. Additionally, fluorescent 
and corresponding phase-contrast (10X) images were captured by EVOS cell imaging system 
(Thermo-Fischer Scientific, USA). 
 
2.2.7 Assessment of plasmid internalization by qPCR analysis 
hASCs seeded on soft and stiff substrates were transfected for 1 hour using the GFP plasmid. Cells 
were thoroughly washed several times with PBS to remove the excess of the plasmid. Cells were 
then trypsinized and counted to obtain a final cell suspension of 1×103/mL. Cells were centrifuged 
at 1000 rpm for 5 minutes, and the corresponding pellets were resuspended in 100 µL PBS and 
freeze-thawed to lyse the cell membrane at -80 °C [190]. One microliter of this lysate suspension 
containing the plasmid was mixed with 10 µL KiCqStart SYBR Green Master Mix, 2 µL of the 
forward and reverse primer for GFP gene and 5 µL of RNAse-free water. All of the reactions were 
performed using a Mastercycler Realplex (Eppendorf, Germany). The quantity of plasmid 
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internalized by the cells in each group was quantified using a calibration curve obtained in the 
range of 0.9 ng to 30 ng of GFP plasmid. Each dilution of the GFP-plasmid was generated using a 
suspension of the non-transfected hASCs lysate (1×103/mL). Additionally, GFP-plasmid dilutions 
were also obtained in RNAse-free water to detect undesired contamination. Samples were 
measured in triplicate for each dilution (n=3).  
 
2.2.8 Evaluation of plasmid internalization using fluorescent-labeled plasmid-Lipofectamine 
lipoplexes 
The plasmid was labeled with red fluorescent Rhodamine using the Label IT® TrackerTM 
intracellular nucleic acid localization Kit CX-Rhodamine (Mirus, WI, USA) to visualize the 
plasmid internalization. The process of labeling was achieved following the established protocol 
provided by the kit. The labeled plasmid was complexed with Lipofectamine2000 following the 
procedure reported above. hASCs were transfected for one hour, followed by thorough washing 
with PBS to remove the non-internalized plasmid. Fluorescent and corresponding phase-contrast 
(40X) images were captured by EVOS cell imaging system (Thermo-Fischer Scientific, USA). 
Cell boundaries were defined based on phase-contrast images. The fluorescence intensity was 
quantified based on the integrated density values of each cell using ImageJ. Results were reported 
as mean ± standard deviation (n = 5) and normalized to the number of cells. 
 
2.2.9 qPCR investigation of caveolin and clathrin genes 
Expression of caveolin and clathrin-mediated genes by hASCs was evaluated using qPCR after 1 
and 4 hours post-transfection on the soft (0.5 kPa) and stiff substrates (32 kPa). mRNA was 
extracted from the cells using an RNeasy Mini Kit (Qiagen, Germany) and quantified using a 
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NanoDrop spectrophotometer (Thermo Scientific, USA). Next, mRNA samples were converted to 
cDNA using the High-Capacity cDNA Conversion Kit (Applied Biosystems, USA). Lastly, gene 
expression was measured using a cocktail of predesigned primers and the KiCqStart SYBR Green 
Master Mix (Sigma Aldrich, USA). All of the reactions were performed using a Mastercycler 
RealPlex (Eppendorf, Germany). The fold expression levels were calculated using the relative 
ΔΔCt method. GAPDH was considered as the housekeeping gene, and the results were normalized 
based on the gene expression of hASCs cultured on the softer substrates. 
 
2.2.10 VEGF quantification by ELISA 
hASCs (105 cells/well) were seeded on 6-well plate silicon hydrogels coated with 1% w/v of 
gelatin type A and allowed to grow in α-MEM (2 mL) supplemented with 15% FBS and 1% 
penicillin/streptomycin (Thermo-Fisher Scientific, USA) at 37 °C and 5% CO2. Cells at 70-80% 
confluency were transfected with VEGF-165 plasmid using Lipofectamine2000 reagent in 
incomplete α-MEM. Supernatants were collected 72 hours after transfection. Quantification of 
VEGF expression was carried out using an enzyme-linked immunosorbent assay (ELISA, R&D 
Systems, Minneapolis, MN) according to the manufacturer's protocol. The amount of VEGF 
released was quantified by ELISA using a standard calibration curve ranging from 32 pg/mL to 1 
ng/mL. Results were normalized based on the concentration of VEGF obtained from the media 
recovered after 72 hours in the soft substrates (n=3).  
 
2.2.11 HUVEC migration assay 
Human umbilical vein endothelial cells (HUVECs) (Lonza, Walkersville, MD) between passages 
6-9 were cultured in 24 well plates (2 × 104 cells/well) in endothelial growth medium (400 µL) 
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(EGM-2 BulletKit, Lonza, Walkersville, MD) without the addition of VEGF and rhFGF-B. After 
reaching confluency, scratches were made in the cell monolayer using a cell scraper. Cells were 
washed thoroughly with PBS to remove all the floating cells. Media containing VEGF was 
collected from stiff and soft substrate groups after 72 hours of transfection (100 µL). Then, 
HUVECs were allowed to migrate through the scratch for 12 and 24 hours. Cells were stained with 
calcein, and corresponding fluorescent images were taken in the same positions along with the 
scratch at 12 and 24 hours. HUVECs that did not receive any growth factors were considered as 
control groups. The percentage of area covered by HUVECs during the migration was calculated 
using ImageJ software. The original scratch area was calculated based on preliminary images taken 
immediately after the scratch was formed (n=3).  
 
2.2.12 Statistical analysis 
Statistical analysis for area calculation covered by HUVECs in the scratch assay was performed 
using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test to 
determine any significant differences between groups at each time point. For all other analyses, a 
t-test (non-parametric) was used to compare two groups. All analyses were carried out with 










2.3 Results and discussion 
2.3.1 Effect of substrate stiffness on the cell morphology  
As the first step of our investigation, we studied the effect of gelatin-coated silicon hydrogel 
stiffness on the morphology and cytoskeletal arrangement of hASCs. Soft (0.5 kPa) and stiff (32 
kPa) substrates were chosen to resemble the stiffness of adipose and bone tissues, respectively 
[191]. hASCs displayed a diverse morphology on the different substrates, as indicated by 
immunofluorescent staining (Figure 2.1A and Figure S2.1). Cells seeded on the stiffer hydrogels 
showed an elongated morphology characterized by a larger surface cell area (4173 µm2) with 
respect to the hASCs on the softer hydrogels (2195 µm2) (Figure 2.1B). Additionally, paxillin 
staining was carried out to investigate the differences in cell focal adhesion expression [192]. A 
greater focal adhesion area was observed for the hASCs seeded on the stiff hydrogels, and this 
result is congruent with previous reports that investigated paxillin expression in other cells lines 
[193] (Figure 2.1C). Aside from a change in the focal adhesion area, a higher number of actin 
stress fibers was quantified in the hASCs on the 32 kPa hydrogels (Figure 2.1D).  Similar results 
were also found in a study comparing the percentage of actin stress fibers in human fibroblasts 
seeded on poly(dimethylsiloxane) and polyacrylamide hydrogels presenting stiffness values 
ranging from 5 kPa to 2 MPa. Fibroblasts seeded on the stiffer matrix presented a more aligned 
distribution of F-actin and a higher cell area [193]. 
Additionally, the average local stress magnitude exerted by the cells on the substrates was 
calculated based on constrained Fourier transform traction (FTTM). Results confirmed that hASCs 
seeded on stiffer hydrogels displayed a higher traction force with an increase in the mean value 
from 0.5 MPa to 5.7 MPa (Figures 2.1E-F). This difference can be attributed to the increase in 
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tension within the networks of actin fibers in the cell’s cytoskeleton, and furthermore, the cells on 
stiffer substrates exhibited reduced cytoskeletal mobility.  
 
Figure 2.1 Influence of substrate stiffness on hASC morphology and cytoskeletal remodelling. A) 
(i) Schematic representing the main changes in cytoskeletal composition and focal adhesion 
distribution observed by culturing hASCs on soft and stiff hydrogels. Cells cultured on softer 
substrates displayed reduced cell surface area, lower total area of focal adhesions, and reduced 
formation of actin filaments. (ii) Immunofluorescence staining of hASCs seeded on soft (0.5 kPa) 
and stiff (32 kPa) silicon hydrogels pre-coated with a solution of gelatin 1% w/v. Cells were stained 
with Alexa Fluor 488 Phalloidin to visualize actin stress fibers (green) and with Diamidino-2-
phenylindole dilactate (DAPI) to stain the nuclei (blue). In addition, paxillin staining (red) was 
carried out to identify the area of focal adhesion. Scale bar = 50 µm. B) Quantification of cell area 
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of hASCs cultured on the two different substrates. Results are reported as mean ± standard 
deviation (n=10). C) Quantification of the total area of focal adhesions expressed by hASCs on the 
different substrates. Results are calculated based on the red fluorescence intensity obtained from 
the immunofluorescent staining for paxillin expression (n=7). D) Actin stress fibre quantification 
obtained by counting the number of actin stress fiber on each cell at 40X magnification. Results 
are reported as mean ± standard deviation (n=9). E) Phase contrast pictures and traction map 
images of hASCs cultured on soft and stiff silicone hydrogels. Scale bar = 80 µm. F) Root-mean-
square (RMS) traction values of hASCs indicated an increase in cell traction on the stiffer substrate 
(n=7). G) RhoA gene expression in hASCs seeded on the different substrates after 24 hours. Results 
were normalized based on the gene expression of cells cultured on the softer substrates (0.5 kPa) 
n=3. Results are reported as mean ± standard deviation * = p < 0.05, ** = p < 0.01 and *** = p < 
0.001. 
 
This change in mobility is also evident by the increase in measured traction forces [189, 194]. 
These findings were further confirmed by qPCR analysis. Specifically, we evaluated the 
expression of RhoA gene, which regulates the assembly of both contractile actomyosin filaments 
and focal adhesion complexes. RhoA was found to be upregulated in the 32 kPa group with a 2.1-
fold increase compared to the softer hydrogel group (Figure 2.1G) [195]. 
 
2.3.2 Effect of substrate stiffness on the intracellular internalization of 
Lipofectamine/plasmid complexes 
After studying the effects of substrate stiffness on cell activity and cytoskeletal remodeling, we 
proceeded to evaluate the effects of substrate stiffness on the efficiency of gene delivery to hASCs. 
Following our previous observations, we hypothesized that an increase in the number of actin 
stress fibers would promote the internalization of the Lipofectamine-DNA complexes (lipoplexes) 
and therefore increase the transfection efficiency (Figure 2.2A). The Lipofectamine used in this 
study has a mean diameter of 346.96 ± 34.42 nm and a positive zeta potential value of 15.65 ± 
0.89 as measured by dynamic light scattering (DLS) analysis. Rhodamine-tagged plasmids were 
electrostatically complexed with Lipofectamine, and DLS analysis confirmed the formation of the 
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complex (Figure 2.2B). For instance, the lipoplexes displayed an increase in the mean diameter 
value as well as a change in the zeta potential measurement from positive to negative values. 
Similar results were found in other reports investigating the formation of a complex between 
plasmid DNA and cationic liposomes [196]. The lipoplexes were used to transfect hASCs seeded 
on the soft and stiff silicon hydrogels. The process of internalization was evaluated one hour post-
transfection. Subsequently, cells were imaged to visualize the quantity of plasmid internalized 
(Figure 2.2C). Quantification of the fluorescence intensity of the rhodamine-tagged plasmid 
revealed a higher presence of plasmid DNA in the hASCs cultured on the 32 kPa hydrogels. A 
three-fold increase in the fluorescent intensity was detected in the more rigid hydrogels with 
respect to the softer substrates (Figure 2.2D). This trend was further confirmed by qPCR analysis 
to determine the quantity of plasmid that was internalized into the cells (Figure 2.2E) [190]. The 
amount of plasmid internalized was measured based on a calibration curve obtained by qPCR 
analysis of different concentrations of GFP plasmid (0.9 ng to 30 ng) in the cell lysates (Figure 
S2.2). As proof of concept, we also transfected hASCs with a green fluorescent protein (GFP) 
plasmid using Lipofectamine. hASCs seeded on the stiff substrates displayed a higher GFP 
expression as confirmed by FACS analysis and fluorescent imaging of GFP positive fluorescent 
cells (Figure S2.3). Our findings suggest that the differences in cell morphology and cytoskeletal 
remodeling play a fundamental role in influencing the cell’s ability to uptake the lipoplexes. These 
results are in agreement with other reports studying the effects of matrix elasticity as the main 
mediator of cellular endocytosis in other cell lines. For instance, fibroblasts, myoblasts, and bone 
marrow stromal cells displayed higher internalization of fluorescently labeled DNA when seeded 
on the stiffer fibronectin-conjugated poly(ethylene glycol) diacrylate hydrogels (670 kPa) with 







Figure 2.2 Effect of substrate stiffness on lipoplexes internalization. A) Schematic indicating the 
internalization efficiency of lipoplexes on hASCs adhering to substrates with different stiffness. 
Cells seeded on 32 kPa substrate internalized a higher quantity of plasmid DNA. B) Mean diameter 
and ζ-potential results obtained by DLS analysis of Lipofectamine2000 and lipoplexes. C) Bright 
field images of hASCs seeded on soft and stiff substrates show the presence of internalized red-
fluorescent lipoplexes. Scale bar = 50 µm. Corresponding fluorescent images displaying the red 
fluorescent complexes (white arrows). Cell boundaries are shown with a yellow line in the 
fluorescent images. Scale bar = 50 µm. D) Quantification of the fluorescence intensity of the 
rhodamine-tagged plasmid performed using image analysis (n=5). E) Quantification of plasmid 
internalization in hASCs seeded on soft and stiff substrates by qPCR analysis. Results are reported 





2.3.3 qPCR analysis of caveolin and clathrin genes 
We also investigated the expression of the genes involved in endocytosis to define the role of actin 
stress fibers in regulating the internalization of the lipoplexes. We studied the gene expression of 
several key proteins directly involved in both caveolae and clathrin-mediated endocytosis 
pathways since both uptake mechanisms are commonly activated in the presence of 
Lipofectamine2000 complexes [198]. The genes and primers used as well as the functions of each 
gene have been reported in the supplementary info (Table S2.1, Table S2.2, Supporting 
Information). The gene expression profile of hASCs was evaluated 1 hour and 4 hours post-
transfection with lipoplexes. These two different times points were selected based on previous 
studies investigating the trafficking processes of the lipoplexes within the cytosol. Lipoplexes 
commonly bind with the cell membrane followed by association with actin fibers within the first 
hour upon transfection. Subsequently, lipoplexes can migrate to the perinuclear region through 
 
 
Figure. 2.3 Schematic of the process of endocytosis through caveolae-mediated pathway. This 
process is divided into three steps: (1) Dynamic of caveolae at the plasma membrane, (2) Caveolae 




active transport using microtubules within the next four hours, as shown in other reports (Figure 
2.3) [199]. 
According to the qPCR results, caveolin-mediated genes were upregulated in the cells cultured on 
the 32 kPa substrate (Figure 2.4A), which confirmed the role of substrate stiffness as an indirect 
regulator of endocytosis. Specifically, Filamin A (FLNA) and Abl tyrosine kinases-1 (ABL1) genes 
were more expressed in hASCs cultured on the stiffer silicon hydrogels. Both genes are essential 
regulators of caveolae formation and migration. Filamin A is a protein that participates in the later 
migration of caveolae membrane and regulates the interaction between caveolin 1 (CAV1) and 
actin stress fibers. A depletion of the FLNA gene is commonly associated with an alteration in the 
caveolae dynamic and a reduction in the caveolae formation. Additionally, Abl tyrosine kinase-1 
controls the polymerization of actin stress fibers and regulates actin interaction with CAV1. CAV1 
and CAVIN1 genes were instead only upregulated after 4 hours, indicating a later expression of 
these proteins essential for caveolae formation. The higher upregulation of all the selected genes 
is justified by the increased presence of actin fibers in hASCs cultured on the stiffer hydrogels. 
Finally, β1 Integrin ITGB1 was upregulated after 1 hour of transfection in the 32 kPa group, which 
is indicative of stabilization of microtubules that are involved in the cellular trafficking of caveolae 
and recycling of CAV1 to the plasma membrane [18, 185]. Overall, the upregulation of all the 
analyzed genes can be explained by the greater presence of well-aligned actin fibers in the hASCs 
seeded on the stiffer substrates. 
On the contrary, no significant differences were found among clathrin-mediated genes in the two 
tested groups (Figure 2.4B). A possible explanation is that actin only plays a primary role in the 
caveolin-mediated pathway, while its contribution to clathrin-mediated endocytosis is reported to 
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be secondary. For instance, actin is not necessary to promote endocytosis of transferrin, which is 
a common ligand used to investigate clathrin-mediated endocytosis.  
Another explanation for the predominance of a caveolin-mediated pathway is that the size of the 
lipoplexes used in this study was larger than 200 nm (482.07 ± 33.01 nm) as evaluated by DLS 
analysis. Clathrin-mediated endocytosis becomes the predominant mechanism of internalization 
only with nanomaterials characterized by a diameter of less than 200 nm [200]. 
 
2.3.4 Evaluation of VEGF secretion and activity 
Finally, we evaluated how the changes in plasmid internalization affected the cell’s ability to 
transiently express angiogenic growth factor. hASCs seeded on the different substrates were  
 
Figure 2.4 qPCR analysis of caveolin and clathrin genes regulating the process of endocytosis 
of lipoplexes. A) Fold increase expression of the main genes involved in caveolin endocytosis 
pathways after 1 and 4 hours of lipoplexes internalization. B) Fold increase expression of the 
main genes regulating clathrin endocytosis pathways after 1 and 4 hours of lipoplexes 
internalization. Results are normalized based on the gene expression of hASCs cultured on the 
soft substrate (0.5 kPa) (n=3).  *= p < 0.05, ** = p < 0.01. 
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transfected with plasmid DNA encoding for the human VEGF-A gene.  
 
Figure 2.5 Modulation of VEGF expression of hASCs transfected on silicon hydrogels with 
different stiffness. A) Fluorescence images of HUVECs stained with calcein. Scratches were 
made at time zero on HUVEC monolayer. Cells were allowed to migrate into the void area for 
24 hours. The conditioned media in the soft and stiff group was supplemented with VEGF 
secreted by hASCs after 72 hours post-transfection. No VEGF and recombinant human 
fibroblast growth factor-B (rhFGF-B) were present in the media of the control group (Ctrl-). 
Scale bar = 200 µm. B) Quantification of the surface area covered by HUVECs after 
proliferation through the original scratches at 12 and 24 hours. The area covered was calculated 
based on the original area of the scratches at time zero.  C) Quantification of VEGF expression 
by ELISA after 72 hours post-transfection. Results are normalized based on the VEGF 
expression of hASCs cultured on the soft substrate (0.5 kPa).*= p < 0.05, ** = p < 0.01, *** = 
p < 0.001. 
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While hASCs possess a natural ability to produce angiogenic growth factors, this inherent 
capability can be augmented by using gene delivery and controlling the physical properties of the 
substrate on which hASCs are seeded [201].  
Higher gene transfection efficiency observed in hASCs cultured on the stiffer substrates resulted 
in a greater production of VEGF, which was evaluated by human umbilical vein endothelial cells 
(HUVEC) migration assay and ELISA quantification [202]. HUVEC migration was monitored 
over time, and a larger migration area was evident after 24 hours in the group exposed to VEGF  
produced by hASCs cultured on the 32 kPa hydrogels (Figure 2.5A-B). Finally, a four-fold 
increase in VEGF concentration was found in the media of the 32 kPa sample compared to the 0.5 

















This study highlights the importance of substrate stiffness as an essential regulator of cellular 
cytoskeletal remodeling and internalization of exogenous genes in hASCs. hASCs displayed a 
higher cell area, increased focal adhesion expression, and a greater amount of actin stress fibers 
when seeded on stiffer substrates (32 kPa). These changes in cellular morphology and cytoskeletal 
organization directly controlled the process of lipoplexes delivery. Specifically, the role of actin 
stress fibers in the process of endocytosis of lipoplexes has been confirmed, defining its direct 
contribution in plasmid internalization. Genes involved in the regulation of caveolae-mediated 
endocytosis were upregulated in hASCs seeded on stiffer substrates 4 hours post-transfection.  
These interesting findings have been directly implemented to augment the angiogenic potential of 
hASCs. hASCs normally secrete VEGF as one of the regulators of their proliferation and 
differentiation into adipogenic, chondrogenic, and osteogenic lineages [203].  The secretion of this 
growth factor can be controlled by nanocarrier-based gene delivery to obtain a selective angiogenic 
protein expression [204]. In this study, we have successfully demonstrated how the efficiency of 
a conventional transfection approach based on Lipofectamine2000 can be augmented simply by 
altering the stiffness of the substrate. Precisely, upon transfection with a plasmid encoding for 
VEGF, we observed a higher VEGF secretion for hASCs seeded on the stiffer substrates. Overall, 
these findings demonstrate how it is possible to control specific cellular functions and augment 







CHAPTER 3. Intracellular delivery of exogenous macromolecules 





Physical techniques for intracellular delivery of exogenous materials offer an attractive strategy to 
enhance the therapeutic efficiency of stem cells. However, these methods are currently limited by 
poor delivery efficiency as well as cytotoxic effects. Here, a high throughput microfluidic device 
is designed for efficient (∼85%) cytosolic delivery of exogenous macromolecules with minimal 
cell death (less than 10%). The designed microfluidic device enables the generation of transient 
pores as the cells pass through the micron-sized constrictions (6-10 µm), leading to the passive 
diffusion of extracellular cargos into the cell cytosol. Specifically, the microfluidic system is 
designed to induce a double deformation on the cell membrane at the squeezing zones to maximize 
intracellular delivery. Additionally, the flow rate, ionic concentration, and the molecular weight of 
the cargo are optimized for maximum efficiency. The optimized device enables cytosolic diffusion 
of small (3 kDa) and large molecules (70 kDa) without inducing any apoptotic effect. Overall, this 
double cell deformation platform offers new opportunities to rapidly and efficiently deliver 
extracellular cargo into stem cells without affecting their viability and functionality. 
 
 
Modaresi S., Pacelli S., Subham S., Dathathreya K., Paul A., Intracellular delivery of exogenous 
macromolecules into human mesenchymal stem cells by double deformation of the plasma membrane, 




Intracellular delivery of exogenous materials can be useful for many research applications ranging 
from gene therapy, cancer treatment, and cellular tracking for diagnostic purposes [205-210]. 
However, the method of delivery should be efficient and selective without compromising cell 
viability or cell functionality. Various approaches have been investigated to promote the 
intracellular delivery of macromolecules, including carrier-based strategies as discussed in the 
previous chapters [176].  
Alternative solutions are the ones that provide the permeabilization of the cell membrane to enable 
the passive diffusion of extracellular cargo. For example, electroporation and sonoporation take 
advantage of the disruption of the plasma membrane using different sources of energy to directly 
deliver target molecules into the cytoplasm. In sonoporation techniques, the cells vibrate at a 
constant frequency by continuous ultrasound waves. As a result, gas bubbles are formed in the 
liquid, leading to an increase in cell membrane permeability [165, 169]. The limitation associated 
with this technique is the need for strong ultrasound pulses to promote high internalization 
efficiency, which causes extensive plasma membrane damage and cell death (50% viability) [134, 
211].  Additionally, electroporation is another method that generates rapid high-voltage electric 
pulses to form an electric field responsible for the formation of temporary pores [139].  However, 
the intense electrical fields can cause significant damage to the delivered cargo as well as 
denaturation of intracellular proteins [159, 212, 213].  
Creating small transient pores in the cell membrane by simple mechanical deformation can also 
offer a new paradigm for rapid and effective delivery of exogenous macromolecules of interest 
[214]. As reported by other groups, this can be achieved by passing the cells through micron-sized 
constrictions [215, 216]. The deformations generate transient pores on the cell surface, leading to 
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passive diffusion of extracellular cargos into the cytosol [172, 173, 217]. Depending on the 
dimensions of the target cell, precise control on cell deformation can be achieved by squeezing 
them through different types of geometries with constrictions that are approximately half of the 
cell diameter [171, 218]. This technique offers the advantage of being rapid and efficient without 
the need for a costly apparatus or an external source of energy. In fact, the driving force required 
for the disruption of the cell membrane can be supplied primarily by the flow of the cell suspension 
passing through the channels of the microfluidic chips.  
In this work, we report an efficient and high throughput strategy to deliver extracellular cargos 
into human mesenchymal stem cells by a double deformation of the cell membrane (i.e., 2-step 
deformation). Particularly, we have fabricated and tested two different microfluidic designs to 
generate the pore formation and induce passive diffusion of extracellular cargos into human 
adipose-derived stem cells (hASCs). This cell source was selected for the study because of their 
ease of harvest [130], and great potential in regenerative medicine, as shown in promising pre-
clinical and clinical trials [219-222]. The applicability of this new technique on other cell types, 
such as NIH 3T3 fibroblasts, were also tested. Several parameters, such as the chip geometry, flow 
rate, gap size, as well as the ionic concentration in the delivery medium were optimized to enhance 
internalization efficiency. Different molecular weights of the model macromolecule dextran 
fluorescein isothiocyanate (Dex-FITC) were tested to determine the suitable size range of cargo 
that could be delivered using the fabricated microfluidic chips.  High cell viability (higher than 
90%), limited cell apoptosis, and preservation of stemness were achieved using the optimized 
microfluidic device. Furthermore, the study investigates the expression of several genes involved 
in the process of cytoskeletal remodeling and membrane resealing post-deformation using the 
microfluidic chip. Overall, here we present a potentially transformative cellular engineering tool 
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to drastically enhance intracellular delivery of exogenous macromolecules without compromising 
cell viability and their functionality.  
 
3.2. Materials and Methods 
3.2.1. Fabrication of the silicon master molds 
As the first step, a silicon wafer was treated with hexamethyldisilazane (HMDS) for 30 minutes at 
150ºC before the coating with a thin film of the SU-8 2015 negative photoresist (Microchem, 
Newton, MA). After treatment, the wafer was allowed to cool at room temperature. A photoresist 
was applied on the pre-treated wafer using a spin coater rotating at 3000 rpm for 30 seconds to 
obtain a layer with a thickness of 15 µm. The wafer was subsequently heated at 65°C for 2 minutes 
and at 95°C for an additional 2 minutes to evaporate the solvent from the SU-8 layer (soft baking) 
prior to UV crosslinking (Photronics, INC). Two distinct chrome-coated photomasks have been 
generated by using AutoCAD (Autodesk), and the pattern was transferred to the silicon wafer 
using contact type mask aligner (ABM, Inc.). UV light at 365 nm was used to crosslink the 
photoresist and the time of exposure (5-10 seconds) was varied based on the energy level of the 
UV lamp, which was checked before each UV treatment. Subsequently, the UV-treated wafers 
were baked at 95°C for 10 minutes to ensure the completion of the crosslinking process. The non-
crosslinked photoresist was removed by washing the wafer in the SU8-developer solvent. Finally, 
the developed wafer was cured at 150°C for 2 hours (hard bake) to anneal any surface cracks that 
are evident after development. The successful fabrication of the micro-constrictions with the 
correct geometry and size was confirmed by visual inspection using a bright field microscope. 
Master molds on the wafer containing micro-constrictions displaying a gap distance larger or 
smaller than 1 µm with respect to the optimal value were discarded. Additionally, the thickness of 
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the master molds was monitored with a profilometer to ensure the obtainment of channels with a 
height of around 15±1 µm. Overall, two separate geometry designs have been fabricated with 
distinct scatter and squeezing areas. The micro-constrictions gaps were varied from 6 to 10 µm to 
ensure efficient cell squeezing.  
 
3.2.2 Fabrication and characterization of the PDMS microfluidic chips  
The SU8-2015 master molds prepared, as described in section 2.1 were used to fabricate the 
microfluidic chips made of polydimethylsiloxane (PDMS). Before the addition of the PDMS pre-
polymer solution, the surface of the silicon SU8-2015 molds was treated with 
trimethylchlorosilane (TMCS) for 30 minutes in a vacuum chamber. This step was necessary to 
ensure the easy removal of the PDMS from the wafer after the curing process. The PDMS 
prepolymer solution and the curing agent (Sylgard 184 silicone elastomer kit, Dow Corning) were 
mixed in a 10:1 ratio. The mixture was de-gassed and poured onto the silicon master molds and 
cured at 75°C for 3-4 hours. After careful removal of the cured PDMS from the wafer, holes of 1 
mm in diameter were punched in the PDMS to create the corresponding inlets and outlets of the 
final microfluidic chips. Finally, an oxygen plasma treatment for 40 seconds was used to bond the 
PDMS mold to the glass slides and seal the microfluidic channels. The bonded devices were kept 
at 90°C for 3 hours to ensure permanent bonding. Tygon tubes (1/16 OD  0.02" ID) were inserted 
in the inlet and outlet holes of the PDMS chips using isopropanol to secure the insertion of the 
tubes. The PDMS chips were placed on a holder with double-sided conductive carbon tape sputter-
coated with gold (35 mm) to visualize the channels and confirm the correct size of the different 
micro-constrictions. The microfluidic chips were imaged at an acceleration voltage ranging from 
1 to 10 kV with an in-lens detector using SEM. 
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3.2.3 COMSOL analysis of the flow velocity in the microfluidic chips 
COMSOL simulation was performed to ensure that the flow velocity was uniform in every channel 
of both microfluidic devices. The input velocity for the simulations was calculated based on the 
flow rate and the corresponding device geometry used during each experiment. Simulations were 
run in laminar flow conditions considering water as the fluid. Series of simulations were performed 
with a different number of elements to check for convergence.  
 
3.2.4 Evaluation of calcium and PBS concentration on the delivery efficiency of Dex-FITC 
hASCs (passages 2-5) were collected from the flasks by trypsinization. The cell suspension in α-
MEM was subdivided into small aliquots containing 200,000 cells each. hASCs were centrifuged 
at a speed of 1.5 g for 5 minutes. The media was discarded, and the pellet was resuspended in 0.5 
mL PBS 1X containing three different amounts of CaCl2 (0, 1 and 2mM) and dextran fluorescein-
isothiocyanate (Dex-FITC) 3 kDa (Sigma Aldrich) at the constant concentration of 0.25 mg/mL. 
The cell suspension was then injected into the microfluidic chip at the constant flow rate of 150 
µL/min using a microfluidic pump (Harvard apparatus). Cells were collected at the outlet and 
allowed to recover for 5 minutes post-treatment. Subsequently, the cell suspension was centrifuged 
at 1.5 g for 5 minutes, and the supernatant was carefully removed. The cell pellets were 
resuspended in 350 µL of PBS solutions containing the corresponding concentrations of CaCl2 
used to deliver Dex-FITC before the treatment. 150 µL of a trypan blue 0.4% w/v solution was 
added to the cell suspension to reach a final concentration of 0.1% w/v and quench the extracellular 
fluorescence of Dex-FITC. The delivery efficiency of Dex-FITC based on the concentration of 
CaCl2 added to PBS was analyzed by Attune NxT flow cytometer (Thermo-Fischer Scientific, 
USA), and the percentage of fluorescent cells for each group was quantified (n=3). Corresponding 
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fluorescent images of the cell suspensions post-treatment for the different groups were taken using 
a fluorescent microscope (Zeiss). A similar procedure was followed to evaluate the optimal 
concentration of PBS (KCl, KH2PO4, NaCl, Na2HPO4-7H2O, no calcium, no magnesium) 
necessary to maximize the delivery efficiency of Dex-FITC. The only difference was that hASCs 
were resuspended in PBS solutions at different concentrations ranging from 1X to 0.5X before 
being deformed through the microfluidic device. All the solutions of PBS tested contained the 
same concentration of Dex-FITC (0.25 mg/mL).  
 
3.2.5 Evaluation of the delivery efficiency of Dex-FITC at different molecular weights (3 and 
70 kDa) 
Prior to each experiment, the channels of the microfluidic devices were coated with 3% bovine 
serum albumin (BSA) for 15 minutes to increase the hydrophilicity of the surface of the PDMS 
microchannels. Each device was flushed with phosphate buffered saline (PBS) to wash any residue 
of BSA.  Human adipose-derived stem cells (hASCs) from female donors between the age of 31 
and 45 years old were purchased from Rooster Bio. Passages 2-5 were used for all the experiments. 
Prior to the experiments, cells were cultured in traditional 2D conditions (3.3×103 cells/cm2) using 
hASCs High-performance media (Rooster Bio media) at 37℃ and 5% CO2 containing 2% of FBS. 
Additional studies were performed using NIH 3T3 fibroblasts, which were cultured in DMEM 
(Gibco) at 37℃ and 5% CO2 containing 10% of FBS. 
Both cell lines were suspended in PBS 1X (0.4106 cells/mL) with no calcium and containing 
dextran fluorescein-isothiocyanate (Dex-FITC) (Sigma Aldrich) at the concentration of 0.25 
mg/mL. Two different molecular weights of Dex-FITC (3kDa and 70 kDa) were tested to evaluate 
the efficiency of delivery. The cell suspension was infused through the microfluidic device by a 
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PHD ULTRA™ Syringe Pump (Harvard Apparatus, Holliston, MA) at a controlled flow rate. Two 
different flow rates (150 and 300 µL/min) were tested in all the internalization studies. Cells were 
collected at the outlet and kept for 5 minutes at room temperature. hASCs were then centrifuged 
at the speed of 1.5 g for 5 minutes, and the Dex-FITC solution was discarded. The pellet was 
resuspended in 0.35 mL of PBS 1X containing propidium iodide (PI) (Life Technologies) for 15 
minutes at room temperature. Finally, 150 µL of a trypan blue 0.4% w/v solution was added to the 
cell suspension to reach a final concentration of 0.1% w/v and quench the extracellular 
fluorescence of Dex-FITC. The efficiency of the delivery of Dex-FITC was evaluated by 
monitoring the percentage of positive fluorescent cells. The results were reported as the mean ± 
deviation standard (n=3). 
 
3.2.6 Plasmid DNA delivery  
The microfluidic devices designed in this study were also tested for the delivery of large plasmid 
DNA encoded for the green fluorescent protein (GFP). The DNA plasmid used for this study had 
about 4,000 bp and a corresponding molecular weight of 2,600 kDa. A few changes were made to 
guarantee the successful internalization of the plasmid compared to the delivery process described 
in section 3.2.5. hASCs were introduced in the microfluidic chip at the cell density of 2.6106/mL 
in OptiMEM medium containing 100-300 µg/mL [179]. After deformation and internalization of 
the plasmid, the cell suspension was allowed to recover for 15 minutes at room temperature. Cells 
were seeded in 12 well plates and allowed to grow for 24 hours. Fluorescent images were taken to 
visualize the successful transfection with GFP with EVOS Auto Fl microscope. Additionally, cells 
were trypsinized and analyzed using flow cytometry to quantify the mean fluorescent intensity 
(MFI) of hASCs expressing GFP. The results were expressed as mean ± deviation standard (n=3). 
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3.2.7 Assessment of apoptosis and qPCR analysis   
hASCs were stained for the presence of Annexin A5, which is used to detect apoptotic cells, which 
express phosphatidylserine on their cell membrane. Before the experiment, hASCs were passed 
through the microfluidic device at different flow rates. Cells were collected and seeded in a 24 
well-plate for 24 hours. As a control group, hASCs were not squeezed through the microfluidic 
device and cultured in Rooster Bio media containing 10% of FBS for 24 hours. 
hASCs were then collected by trypsinization and washed twice with cold PBS. The Annexin A5 
binding buffer was used to resuspend hASCs in a final cell density of 1×106 cells/ mL. 10 µL of 
Annexin A5-FITC was added to the resuspended hASCs. Cells were then incubated in the dark for 
30 minutes. Additionally, 1 µL of propidium iodide was added to the cells to stain necrotic cells. 
The apoptosis ratio of hASCs was immediately measured using the Attune NxT flow cytometer 
(Thermo-Fischer Scientific, USA). Aside from Annexin A5 staining, qPCR analysis of key 
apoptotic genes was carried out. Gene expression of BAX, BAD, BAK, BBC3 was monitored right 
after the deformation through the microfluidic chips and after 24 hours. hASCs that did not 
undergo a step of deformation were used as a control group. mRNA was extracted from the cells 
using RNeasy Mini Kit (Qiagen, Germany) and quantified using a NanoDrop spectrophotometer 
(Thermo Scientific, USA). Next, mRNA samples were converted to cDNA using the High-
Capacity cDNA Conversion Kit (Applied Biosystems, USA). Finally, the gene expression was 
obtained by using pre-designed primers and the KiCqStart SYBR Green Master Mix (Sigma 
Aldrich, USA). All reactions were performed using a Mastercycler RealPlex (Eppendorf, 
Germany). The fold expression levels were calculated using the relative ΔΔCt method (n=4). 
GAPDH was used as the housekeeping gene, and results were normalized based on the gene 
expression of the control group [223]. 
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Following the same procedure, qPCR analysis was performed to evaluate possible changes in the 
expression of stemness-related genes including Nanog, SOX2, KLF4 at 0 and 24 hours post-
deformation using the microfluidic device. Similarly, we have investigated changes in the 
expression of cytoskeletal genes such as ACTA1, MYH2, LAMA1, and KRT18 involved in the 
process of cytoskeletal remodeling after membrane resealing. 
 
3.2.8 Investigation of cytoskeletal remodeling process after membrane rupture 
For this test, two different groups were investigated. The test group consisted of hASCs exposed 
to Cytochalasin D at a concentration of 0.5 µM for two hours [224, 225]. The drug was solubilized 
in dimethyl sulphoxide. The control group consisted of hASCs cultured in normal conditions 
without any drug treatment. Cells from both groups were trypsinized and passed through the 
double deformation device at the flow rate of 300 µL/min and a gap of 8 µm between the 
constrictions. The suspension medium was supplemented with Dex-FITC 3 kDa at the constant 
concentration of 0.25 mg/mL for both groups. Subsequently, the cells were treated following the 
procedure reported in section 2.5, and fluorescent hASCs were detected using flow cytometry. 
Cells were exposed to trypan blue at the concentration of 0.1% w/v to quench the external 
fluorescence of Dex-FITC. The percentage of fluorescent cells were expressed as the mean ± 
deviation standard (n=3). 
 
3.2.9 Statistical analysis 
Statistical analysis was performed using an unpaired t-test and one-way ANOVA (followed by 
Tukey’s multiple comparison test) to determine whether a significant difference exists between 
specific groups. All statistical analyses were carried out with GraphPad Prism Software 6. A p-
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value less than 0.05 indicates statistical significance, which was displayed as *p < 0.05, **p < 
0.01, ***p < 0.001. 
 
3.3 Results and discussion 
3.3.1 Fabrication and characterization of the microfluidic device 
The formation of small transient pores in the cell membrane can be achieved by creating micron-
sized constrictions with a size of half the diameter of the cell [179, 226]. Additionally, the 
arrangement of the micron-sized channels within the microfluidic device plays a fundamental role 
in modulating the extent of deformation the cells are subjected to during the squeezing phase [227]. 
Finally, cells need to be homogeneously distributed in the microfluidic channels to avoid the 
possible risk of clogging, thus enhancing the efficiency of internalization of extracellular cargos. 
Based on these concepts, we have developed a novel microfluidic design which includes different 
alternated sub-units defined as dispersion and squeezing zones (Figure 3.1A). Each microfluidic 
chip has 7 dispersion zones and 12 squeezing zones. The dispersion zone contains pillars made of 
polydimethylsiloxane (PDMS) with a diameter of 20 µm and a height of 15 µm, which are 
separated from one another with a 30 µm gap to ensure the proper dispersion of the cell suspension 
within the different channels of the squeezing zones. The inclusion of a dispersion zone prior to 
the squeezing channels was found to be efficient in preventing the formation of cell agglomerates, 
as demonstrated in another study [228]. The squeezing zone is fabricated with parallel channels to 
ensure a steady flow rate throughout the microfluidic device. This strategy guarantees the 
preservation of the flow in all the other channels if one of them is clogged by the cell suspension. 
We confirmed the presence of a steady flow by simulating the velocity of the flow in each channel 
using COMSOL (Figure S3.1). The squeezing zones were designed following two different 
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patterns. The first one was created by orienting the constrictions to form tunnels of 20 µm in length 
(25 in each squeezing zone), while the second design was obtained by changing the geometry and 
displacing the pillars to avoid the formation of micro-tunnels (50 in each squeezing zone). This 
orientation enabled the formation of squeezing constrictions rather than micro-tunnels. Scanning 
electron microscopy (SEM) images of the two different types of squeezing zones were taken to 
verify the correct disposition and dimensions of the channels (Figure 3.1B-C). The different 
geometry designs were able to deform the cell in two distinct modalities defined as “single” and 
“double” deformations within each squeezing path (20 µm) of the device (Figure 3.1D). The single 
deformation through single channels has already been investigated in other studies [226, 229]. In 
this case, cells are stretched along the direction of the flow leading to the formation of transient 
pores for exogenous cargo internalization. However, in the novel double deformation design, as 
investigated here, it is possible to change the membrane orientation and increase the number of 
deformations the cell can experience in each squeezing path. Our hypothesis is that the cells, while 
undergoing a double deformation, will internalize a larger amount of extracellular material 
compared to the single squeezing strategy. Nevertheless, this is not the only parameter that needs 
to be considered to maximize intracellular delivery. 
 For instance, the ion concentration is another factor that has been shown to affect the 
internalization efficiency of exogenous material and to control the process of membrane resealing 
after rupture [174, 230]. Specifically, there are two distinct plasma membrane repair mechanisms. 
If the pore size generated by squeezing is a few nanometers, cells spontaneously will repair their 
membrane after the injury by following a thermodynamic rearrangement of the phospholipid 
bilayer [231-233]. On the contrary, resealing of membrane ruptures larger than 200 nm in size 
requires the influx of calcium ions (Ca2+) [234, 235]. Mechanical disruption of the cell membrane 
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by using microfluidic devices has been reported to promote the formation of pores with a size 
greater than 200 nm in other studies [175, 179]. Therefore, it was important to evaluate whether 
the delivery efficiency of extracellular cargo Dex-FITC could be affected by the amount of Ca2+ 
as well as other ions present in the delivery medium.  
 
 
3.3.2 Effect of calcium and phosphate buffer concentration on the internalization efficiency 
Upon the cell membrane injury, the influx of Ca2+ enables the fusion of intracellular vesicles 
responsible for the formation of a membrane patch necessary to reseal the bilayer (Figure 3.2A) 
[236]. Based on this mechanism, we tested different Ca2+ amounts (0, 1 and 2 mM) in the medium 
phosphate buffered saline (PBS 1X) to determine the concentration necessary for optimal Dex-
Figure 3.1 Design of microfluidic devices to induce cell deformation. A) Picture showing the 
overall microfluidic device structure composed of 7 dispersion zones and 12 squeezing zones 
(Scale bar = 5 mm). The inset shows a corresponding higher magnification image of the 
microfluidic device (Scale bar = 100 µm). B) and C) Corresponding SEM images of the two 
designs (Scale bars = 20 µm). On the right, insets of both patterns displaying the dimensions of 
the channels and the gap size. D) Schematic represeinting the process of cell squeezing with 
two different deformation modalities (single and double), and corresponding bright field images 
of hASCs squeezed through the single and the double deformation designs (Scale bar = 10 µm). 
Single deformation is a 1-step deformation process, whereas double deformation contains 2-




FITC 3 kDa delivery in hASCs (Figure 3.2B). These concentrations were selected considering the 
physiological range of Ca2+ in the extracellular fluids [237, 238].  We observed the highest delivery 
efficiency in the group without any calcium, and a corresponding decrease in the percentage of 
fluorescent cells as the amount of calcium was increased up to 2 mM (physiological Ca2+ 
concentration) (Figure 3.2C). These results suggest that the influx of Ca2+ after membrane rupture 
may be directly linked to the time required for the complete resealing of the membrane [239]. On 
the contrary, in the absence of Ca2+, the membrane pores remain open for a longer time, and 
therefore, there is a higher chance for internalization of extracellular cargos. These results are in 
accordance with other reports investigating the role of calcium in the delivery of Dex-FITC in 
HeLa cells similarly deformed using a different type of microfluidic device [175]. Aside from Ca2+ 
concentration, cellular membrane deformability can be altered by changing the osmolarity of the 
buffer used for the treatment [240]. To prove this concept, we studied the delivery of the same 
cargo into hASCs by varying the concentration of PBS from 1 X to 0.25 X. No significant 
difference was observed in the delivery efficiency of Dex-FITC 3 kDa when the concentration of 
PBS was varied from 1 X to 0.5 X. However, at 0.25 X PBS the delivery efficiency was much 
higher leading to a 90% of efficiency (Figure 3.2D). This result may be due to the greater 
deformation of the membrane in less concentrated salt solutions resulting in the generation of more 
membrane pores. However, a corresponding increase in cell death was observed by flow cytometry 
analysis as the concentration of PBS was decreased (Figure 3.2E). These findings are consistent 
with another report investigating the role of PBS in intracellular delivery of fluorescent cargos 
using cancer cells [174]. Overall, the absence of calcium and a concentration of PBS equal to 1X 
were the optimal conditions to maximize the delivery efficiency of the model Dex-FITC, and these 





Figure 3.2 Effect of varied ionic concentrations of calcium and PBS on intracellular delivery 
of Dex-FITC in hASCs. A) Schematic showing the process of membrane resealing in the 
presence of calcium. The influx of calcium is responsible for the fusion of intracellular vesicles. 
These vesicles form a membrane patch to reseal the membrane rupture. B) Delivery efficiency 
of Dex-FITC 3kDa in hASCs using PBS 1X with different concentrations of Ca2+. C) 
Corresponding fluorescent images of hASCs loaded with Dex-FITC in the different group 
tested post-treatment (Scale bar = 200 µm). D) Delivery efficiency of Dex-FITC 3kDa in 
hASCs using different concentrations of PBS to evaluate the effect of osmolarity on 
intracellular diffusion. E) Dot plots graphs displaying the population of green fluorescent 
hASCs that have internalized Dex-FITC, and red fluorescent hASCs stained with propidium 
iodide (dead cells). The percentage of dead cells is reported for all the different group tested. 
Results are reported as mean ± deviation standard (n =3). * = p < 0.05, ** = p < 0.01, and *** 




3.3.3 Optimization of the microfluidic parameters for efficient intracellular delivery 
As the second step of this work, we have investigated the effect of gap size, flow rate, design type, 
and molecular weight of the cargo as additional features influencing intracellular delivery. Each 
microfluidic device was able to successfully treat a cell density of 400,000 cells/mL. A set of gaps 
between the micron-sized constrictions for both designs was developed ranging from 6 to 10 µm 
which corresponded to half of the diameter of hASCs (~ 17.5 µm). Two different flow rates (150 
µL/min and 300 µL/min) were tested to verify the impact of the flow velocity on the internalization 
efficiency. Flow rates larger than 300 µL/min were not tested because the designed microfluidic 
chips could not withstand them. Two distinct molecular weights of Dex-FITC (3 kDa and 70 kDa) 
were tested to verify whether the designed microfluidic devices were suitable for the 
internalization of small molecules such as siRNA, miRNA, and oligonucleotides, as well as large 
biomolecules including proteins and enzymes [226]. Finally, as the last parameter, we compared 
the efficiency of the two modalities of squeezing as discussed previously.  
Dex-FITC was selected due to its impermeability through the cell membrane, and only a small 
percentage of cells were able to internalize Dex-FITC 3 kDa and 70 kDa via endocytosis (Figure 
S3.2). The cell suspension containing Dex-FITC was squeezed through the device and allowed to 
recover post-treatment for 5-10 minutes at room temperature. This time has been found to be 
necessary for the resealing of the cell membrane, as demonstrated in another similar study [226]. 
A significant increase in the delivery of Dex-FITC 3 kDa was observed when hASCs were 
squeezed through the narrower gaps in both designs (Figure 3.3A-B). However, once a double 
deformation was applied, a higher internalization was observed. Specifically, a delivery efficiency 
larger than 80% was achieved in this design when using a gap of 8 µm and a flow rate set to 300 
µL/min. In contrast, a decrease to 60% was detected when using the same parameters in the single 
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deformation design (Figure 3.3C). Similar trends were observed in the delivery efficiency 
between the two designs while keeping the other parameters constant (Table S3.1).  These data 
confirm the validity of our hypothesis. It is likely that the cells may experience greater localized 
stress due to the change in membrane orientation when passing through the double deformation 
design compared to the single deformation group. This difference may be responsible for a larger 
number of transient holes in the cell membrane leading to higher diffusion in the cytosol of the 
external molecules as detected by flow cytometry analysis. In other studies, by modifying the 
deformation angles of the constrictions, it was possible to change the orientation of the cell 
membrane during the squeezing phase [174]. This variation led to a larger deformation and higher 
diffusion of exogeneous material into the cytosol similar to our findings. 
The efficiency of internalization in all the tested groups decreased when Dex-FITC 70 kDa was 
delivered. This result indicates that the size of the cargo is an important parameter that can affect 
the delivery efficiency irrespective of the design of the microfluidic device used. Furthermore, a 
significant decrease in the percentage of fluorescent cells was observed with an increase in gap 
size, confirming the data obtained with Dex-FITC 3 kDa. However, with a larger molecule, it is 
more evident the effect of the flow rate on the percentage of delivery for both designs tested 
(Figure 3.3D-E). Finally, the double deformation design exhibited a larger internalization of Dex-
FITC 70 kDa compared to the single deformation group as observed previously. Precisely, an 
increase in positive fluorescent cells from 38% to 53% was detected using flow cytometry when 







A similar trend in the delivery efficiency was observed for the other gaps and flow rates for the 
double deformation design (Table S3.2). We also performed internalization studies using NIH 
3T3 fibroblasts, and a significant decrease in the percentage of Dex-FITC was observed when 
 
Figure 3.3 Effect of gap size, flow rates and geometry (single and double deformation) on the 
internalization of Dex-FITC with different molecular weight in hASCs. A) and B) Delivery 
efficiency of Dex-FITC (3 kDa) in hASCs using single and double deformation, respectively. 
Three different gaps (6, 8 and 10 µm) and two different flow rates (150 µL/min and 300 
µL/min) were tested for each design C) Representative histogram plots displaying a higher 
percentage of green fluorescent cells in the group undergoing double deformation. hASCs were 
squeezed using the same gap (8 µm) and flow rate (300 µL/min) for both designs. D) and E) 
Delivery efficiency of Dex-FITC (70 kDa) using single and double deformation, respectively. 
A decrease in the percentage of positive fluorescent hASCs were found in all the gaps tested 
compared to the results reported for Dex-FITC 3 kDa. F) Representative histogram plots 
obtained by flow cytometry showing a higher percentage of delivery of Dex-FITC 70 kDa in 
the double deformation group compared to the single deformation design. hASCs were 
squeezed using the same gap (6 µm) and flow rate (300 µL/min) for both designs. Results are 
reported as mean ± deviation standard (n =3). ψ and ω are used to indicate significant change 
in delivery compared to gap 6 for the other two gaps at the flow rate of 150 µL/min and 300 
µL/min, respectively (p<0.05). β and λ are used to indicate significant change in delivery 
compared to gap 8 for gap 10 at the flow rate of 150 µL/min and 300 µL/min, respectively 




using a higher molecular weight. (Figure S3.3). Collectively, these data confirmed our hypothesis 
that cells can experience a more impactful squeezing in the double deformation design, and the 
process of internalization was more efficient when smaller gaps and higher flow rates were used. 
We also explored the possibility to deliver biomolecules larger than Dex-FITC 70 kDa. 
Specifically, GFP plasmid was delivered successfully using the double deformation design, 
although the efficiency of transfection was low (less than 10%). The mean fluorescent intensity 
(MFI) of transfected hASCs was similar in both groups at the different flow rates tested (150 and 
300 µL/min) (Figure S3.4). Poor transfection efficiency may be due to several factors. One of the 
primary reasons is the possible plasmid degradation occurring in lysosomes compartments, which 
prevents its successful translocation to the nucleus. Additionally, another possible explanation is 
that the plasmid used in this study had a large molecular weight (~2,600 kDa) and was not 
linearized as reported in a different study [228].  
 
3.3.4 Evaluation of cell viability and apoptosis  
The next step of our investigation was to verify the impact of cell deformation on cell viability. 
Specifically, it was essential to assess whether a double deformation would have any detrimental 
effect compared to the less efficient single deformation design. Cell viability was studied 30 
minutes post-treatment by propidium iodide staining. In both designs, there was an increase in cell 
viability as the gap size increased (Figure 3.4A-B). This trend was expected based on the extent 
of deformation induced by the constriction gap size. Specifically, the highest cell viability value 
was associated with a 10 µm gap, which is slightly higher than half of the hASCs’ diameter. No 
significant change was observed as the flow rate increased from low (150 µL/min) to high (300 
µL/min) except for the double deformation design using a gap of 8 µm. Flow cytometry analysis 
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displayed comparable results in the percentage of positively stained dead cells with propidium 
iodide when comparing the two different designs at the same gap (10 µm) and flow rate (300 
µL/min) (Figure 3.4C). Similar results in the percentage of cell viability were found for both 
designs when comparing all the other parameters (Table S3.3). We also observed a similar trend 
in the cell viability for fibroblasts tested with the two different microfluidic devices (Figure S3.5).  
Overall, considering the efficiency of delivery as well as the cell viability trends, so far described, 
the double deformation design with a gap of 8 µm represented the best option to promote efficient 
delivery without causing a significant change in cell viability. Therefore, to investigate possible 
changes in apoptosis and gene expression of cytoskeletal markers, further characterization was 
performed by using this optimized device. We analyzed the effect of the flow rate on the apoptosis 
of hASCs after 24 hours post-treatment using Annexin A5 staining. Annexin A5 is used to detect 
apoptotic cells that express phosphatidylserine on their surfaces. The results of the different groups 
tested were compared to a control group consisting of hASCs cultured in normal conditions 
without being passed through the microfluidic device. Flow cytometry analysis showed an increase 
in the percentage of apoptotic cells as the flow rate was increased. In detail, an increase from 8% 
to 13% of apoptotic cells was observed, although not statistically significant (Figure 3.4D). 
Similarly, we investigated the gene expression of pro-apoptotic markers such as BAD, BAX, BAK1, 
and BBC3 immediately after squeezing and at 24 hours post-treatment (Figure 3.4E-F) [223]. 
Compared to the control groups, no significant change in the expression profile was observed at 
both time points. Moreover, to demonstrate the lack of changes in stem cell genotype, we 
performed qPCR analysis on the expression of common stemness cell genes including Nanog, 
Sox2, Klf4 after 24 hours post-treatment [241]. No significant change in the profile expression 
compared to the control group was observed after 24 hours post-treatment (Figure S3.6). Overall, 
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these combined results demonstrate the safety of the optimized designed microfluidic device, 
which did not alter cell functionality after the deformation of the cell membrane. 
 
Figure 3.4 Effect of gap size, flow rates and geometry design on viability and apoptosis of 
hASCs passing through the microfluidic device. A) and B) Percentage of cell viability obtained 
after passing the cells through the single and the double deformation design, respectively. 
Similar to the delivery efficiency tests, three different gaps (6,8 and 10 µm), and two different 
flow rates (150 µL/min and 300 µL/min) were tested for each design.  Results are reported as 
mean ± deviation standard (n =3). ψ and ω are used to indicate significant increase in cell 
viability compared to gap 6 for the other two gaps at flow rate of 150 µL/min and 300 µL/min, 
respectively (p<0.05). β and λ are used to indicate significant increase in cell viability compared 
to gap 8 for gap 10 at the flow rate of 150 µL/min and 300 µL/min, respectively (p<0.05). * 
indicates significance between two different flows for the same gap (p<0.05). C) Overlap 
between histogram plots obtained by flow cytometry displaying a similar population of dead 
hASCs stained with propidium iodide for both designs. D) Percentage of apoptotic hASCs 24 
hours post-treatment after passing through the double deformation design at different flow rates. 
The percentage of apoptotic cells was determined by staining hASCs with Annexin V staining 
followed by flow cytometry analysis. E) and F) qPCR analysis of key genes involved in the 
process of apoptosis such as BAD, BAX, BAK1 and BBC3 after 0 and 24 hours post-treatment, 
respectively. hASCs cultured in a well plate without undergoing a process of deformation were 
used as control group. No significant change was observed among the two groups for both time 




3.3.5 Evaluation of the key parameters involved in cell membrane resealing  
Finally, it was essential to understand the role of cytoskeletal rearrangement and cell stiffness in 
the process of membrane repair and cargo internalization in hASCs. Particularly, upon damage of 
the cell membrane calcium enters the cytosol and initiates a cascade of events leading to the 
resealing of the membrane. These include a step of depolymerization of actin fibers followed by 
intracellular vesicle fusion to form a patch necessary to reseal the membrane. Finally, remodeling 
of cytoskeletal components takes place to replace the membrane patch and to form the cortical 
cytoskeleton [234]. Based on these well-known events, it was important to study the regulation of 
several markers involved in the expression of cytoskeletal proteins immediately after membrane 
rupture. We observed a significant upregulation of actin (ACTA1) 3.79 ± 0.7, myosin II (MYH2) 
2.24 ± 0.46, for hASCs undergoing a process of squeezing. These changes compared to the control 
group were not present after 6 hours, indicating an active process of cytoskeletal remodeling 
occurring only shortly after the rupture (Figure 3.5A-B).  
To further confirm the role of actin as the main regulator involved in membrane resealing, we 
induced the depolymerization of actin filaments in the cytoskeletal network prior to the process of 
squeezing. The overall hypothesis is that the stiffness of the cell may be an additional factor 
responsible for the membrane deformability. Precisely, a disruption in the actin cytoskeletal 
network could be responsible for the formation of a larger number of pores during squeezing, 
leading to a higher internalization of extracellular cargo (Figure 3.5C). To test this hypothesis, we 
exposed the cells to the drug Cytochalasin D (Cyto D) for two hours, which inhibits the 
polymerization of actin in hASCs, This mycotoxin is known to penetrate cells and link to actin 
leading to its disruption. After internalization, Cyto D has also been reported to promote a 




Figure 3.5 Assessment of key parameters involved in the process of membrane resealing. A) 
and B) qPCR analysis of the expression of different cytoskeletal genes in hASCs after 30 
minutes and 6 hours post-treatment, respectively. A significant upregulation in the genes was 
observed after 30 minutes indicating an active process of cytoskeletal remodeling. As a control 
group, hASCs were cultured without undergoing a step of deformation. C) Schematic indicating 
the process of cell squeezing with and without the presence of Cytochalasin D (Cyto D), which 
inhibits actin polymerization and disrupts network organization. The hypothesis is that the 
inhibition of actin polymerization will reduce the stiffness of hASCs leading to a higher 
deformability of the membrane and enhanced molecule internalization ability. D) Delivery 
efficiency of Dex-FITC 3kDa in hASCs treated with 0.5 µM Cyto D for 2 hours compared to 
untreated cells. A higher internalization of Dex-FITC was detected in the treated cells. Results 
are reported as mean ± deviation standard (n=3). ** indicates significance between the two 
different groups tested (p < 0.01). E) Corresponding histogram plots displaying positive Dex-
FITC cells treated with 0 µM and 1 µM of CytoD.   
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higher internalization of Dex-FITC after squeezing through the optimized microfluidic device. 
Precisely, an increase in positive fluorescent cells from 60% up to 85% was observed by flow 
cytometry (Figure 3.5D-E). These findings confirmed our hypothesis highlighting the importance 
of cell stiffness and actin network formation as additional parameters to be considered for efficient 
internalization of extracellular cargo.    
 
3.4 Conclusions 
In this work, we have successfully developed and optimized a novel microfluidic device to 
maximize the delivery efficiency of external model fluorescent molecules into hASCs. This 
method is fast and can be used to treat large numbers of cells (0.5 ×106) in a short amount of time 
(< 5 minutes). The process of delivery of Dex-FITC into hASCs was directly influenced by the 
concentration of calcium ions in the medium. Increasing the concentration of calcium led to a 
decrease in  delivery efficiency, suggesting the presence of a calcium-dependent mechanism. Such 
an effect indicates the formation of pores of around 200 nm, as demonstrated by other studies 
[175]. The osmolarity of the solution did not influence the internalization efficiency of Dex-FITC, 
and an increase was detected only for the lower concentration (0.25X). However, at such a low 
amount of PBS, a significant decrease in cell viability was observed. 
Aside from the medium composition, the design of the chip had a profound impact on delivery 
efficiency. A double deformation of the cell membrane in each squeezing path of 20 µm enabled 
a higher internalization of Dex-FITC compared to the single deformation modality. The 
internalization efficiency decreased as the size of the cargo increased, although the optimized 
device could be used to deliver different types of molecules, including plasmid DNA. Overall, 
based on the results, the designed microfluidic chip is ideal for delivering small bioactive 
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molecules with a size below or equal to 3 kDa that can be useful to enhance the therapeutic 
potential of hASCs in future studies. High cell viability was observed irrespective of the squeezing 
modality proving that the double deformation design can be effectively used without inducing cell 
death. 8 µm gap size between the micro-constrictions was found to be the best compromise in 
terms of high delivery efficiency and minimal cell death. More importantly, the process of 
squeezing did not induce any apoptosis and did not significantly upregulate key pro-apoptotic 
genes. Similarly, the stemness of hASCs was preserved 24 hours post-treatment suggesting a 
complete restoration of their functionality. However, additional investigations should be carried 
out in the future to verify whether hASCs can maintain their osteogenic or adipogenic 
differentiation potential. 
Finally, we have analyzed the role of actin stress fibers and stem cell stiffness as additional 
parameters influencing the internalization of extracellular cargo. Our results indicate that hASCs 
undergo a process of cytoskeletal remodeling after the formation of transient pores in the cell 
membrane. However, this process is only occurring within the first-hour post-treatment. In fact, 
the cells were able to restore the expression of these markers to their basal level after 6 hours. 
Finally, inhibiting actin polymerization in hASCs by using Cyto D was responsible for the 
formation of a more flexible cell membrane. The change in cell stiffness led to a higher 
internalization of Dex-FITC. These findings further confirm the role of actin as a key component 
involved in the process of cell membrane resealing, which needs to be accurately considered for 
further studies aimed to maximize the delivery efficiency of extracellular cargo. For instance, a 
thorough characterization based on the stem cell stiffness could be useful to predict which cell type 




CHAPTER 4. Direct intracellular delivery of trehalose into human 
adipose-derived stem cells for efficient cryopreservation  
 
Abstract 
Available strategies to preserve stem cells rely on cryopreservation, and one of the most commonly 
used cryoprotectant agent (CPA) is dimethyl sulfoxide (DMSO). This CPA has been shown to 
preserve stem cells during a freezing/thawing process, although its high toxicity at 37 °C can 
hinder the regenerative potential of stem cells upon transplantation in vivo. A valid alternative to 
DMSO is trehalose, a natural disaccharide that does not pose any risk of cytotoxicity to stem cells 
during freezing/thawing. However, trehalose needs to be delivered intracellularly to be effective 
as a CPA in comparison to the cell-permeable DMSO. This issue is caused by the limited 
permeability of this sugar in the cell membrane that hampers its use for cryopreservation purposes. 
In this work, we proposed the intracellular delivery of trehalose through the creation of transient 
pores by using the designed microfluidic chip discussed in Chapter 3. The goal of this work is to 
promote the intracellular delivery of trehalose into human adipose-derived stem cells (hASCs) to 
promote efficient cryopreservation. To verify the effectiveness of our strategy, the amount of 
trehalose delivered intracellularly was quantified and optimized based on the observed cell 
viability post-cryopreservation. hASCs were also frozen in freezing media containing DMSO and 
used as a standard control group. Several parameters including cell viability, apoptosis, retention 
of stemness, angiogenic growth factor secretion, and differentiation capability through osteogenic 
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Stem cells are a valuable resource for tissue engineering, regenerative medicine, and stem cell-
based therapies [243-248]. Precisely, the global stem cells market size is expected to reach 11,380 
billion dollars by 2021 [249]. Currently, stem cells are being tested as a valid treatment in a variety 
of diseases such as leukemia, myocardial infarction, diabetes, autoimmune, and blood disorders 
[243, 250-252]. Hence, due to their immense value in regenerative medicine, it is important to 
provide a safe method of cell storage post-harvesting which can preserve their stemness and 
prevent any sort of metabolic damage. In addition, stem cell banking reduces the costs associated 
with culturing cells at 37°C and limit the possibility of genetic alteration due to continuous long-
term culture in vitro [253-256]. 
Stem cells can be cryopreserved by using different CPA [257-260]. The most common CPA is  
DMSO, a small amphiphilic molecule, which rapidly penetrates the cell membrane and protects 
cells from irreversible damage during a freezing/thawing process [261, 262]. Despite its efficiency, 
DMSO has been shown to be toxic to cells at 37 °C (body temperature) and requires rigorous 
washing steps for the complete removal from the cells. This drawback limits the availability of 
freshly thawed cells cryopreserved with DMSO for clinical use [263-265]. Additionally, during 
each washing step, about 10% of cells can be lost, making this procedure highly inefficient [241]. 
Finally, DMSO has also been found to induce differentiation in more than 25 human stem cells 
lines [266], and incomplete removal of DMSO has been shown to cause intravascular hemolysis, 
increased serum transaminase levels, cardiac and pulmonary arrest, acute renal failure, and 
seizures [267-269]. As a safer alternative, disaccharides, such as trehalose, can be considered as 
natural CPAs for cryopreservation [262, 270-273]. They offer the advantage of being non-toxic 
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and do not need to be removed after thawing. However, one of the drawbacks associated with this 
type of CPA is the limited permeability across cell membranes [274, 275]. 
Over the past few decades, various approaches have been developed to overcome this issue and 
promote the delivery of trehalose into eukaryotic mammalian cells. The most direct method for the 
controlled delivery of trehalose is microinjection [276-278]. Although useful, this process is 
extremely labor-intensive and cannot be used for all types of cells [139, 271]. Another strategy is 
to introduce trehalose through transporter 1 (TRET 1), which facilitates the selective transport of 
trehalose across the cell membrane [279]. Additionally, endogenous expression of trehalose in 
cells can be achieved by adenoviral transduction [280]. These methods are associated with several 
concerns, including possible cytotoxic effects and the risk of undesired genetic modification [130, 
281]. For these reasons, viral transduction is not considered a safe option with limited applicability 
in a clinical setting.  
Other research groups have investigated alternative strategies for the delivery of trehalose. These 
consist of the synthesis of delivery vehicles such as nanoparticles [241, 272], polymers [282-284], 
cell-penetrating peptides [285], and liposomes [258, 286].  Several limitations are associated with 
these types of carriers, including possible cytotoxic effects, poor stability, as well as poor loading 
efficiency. The listed drawbacks restrict the possible use of these approaches for large-scale stem 
cell banking.  
Additional routes for the delivery of trehalose are based on permeabilization methods that require 
thermal, ultrasound, and electrical (electroporation) forms of energies [167, 287-289]. These 
methods, although effective in enhancing the internalization of trehalose, require thorough 
optimization as they can induce irreversible damage to cells.  
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An alternative solution is to explore techniques aimed to generate transient membrane pores by  
mechanical deformation of the cell membrane. These temporary defects allow the internalization 
of trehalose with high efficiency and limited cytotoxic effects. For example, microfluidic devices 
can be fabricated with micron-sized microfluidic constrictions of around half to one-third of the 
cell’s diameter to generate localized stress on the cell membrane [170-172]. By following this 
approach, the goal of the work discussed in Chapter 4 is to quantify the intracellular delivery of 
trehalose using the optimized microfluidic described in Chapter 3 with the aim to promote efficient 
cryopreservation of human adipose-derived stem cells (hASCs). Specifically, hASCs loaded with 
trehalose will be cryopreserved in freezing media supplemented with extracellular trehalose and 
several parameters including cell viability, apoptosis, stemness, angiogenic growth factor 
secretion, and differentiation capability will be tested post-cryopreservation. hASCs frozen in 
freezing media containing DMSO will be used as a control group for all the studies proposed in 
this work. Overall, the findings of this research will be necessary to validate the efficacy of this 











4.2 Materials and Method 
 
4.2.1 Materials 
D-(+)-Trehalose dihydrate from Saccharomyces cerevisiae, phosphate buffer saline 1X (PBS), 
potassium phosphate monobasic (KH2PO4), potassium phosphate dibasic (K2HPO4), Magnesium 
-chloride (MgCl2), dimethyl sulfoxide (DMSO), ascorbic acid-2 phosphate, β-glycerophosphate, 
dexamethasone, and hematoxylin were purchased from Sigma Aldrich. α-Minimum Essential 
Medium (α-MEM), Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS) 
propidium iodide (PI), 10% goat serum, Mouse anti-human Paxillin antibody, goat anti-mouse 
AlexaFluor 594 antibody, diamidino-2-phenylindole dilactate (DAPI), phalloidin-AlexaFluor488, 
Matrigel Matrix, Gentamicin were purchase from Thermo Fisher Scientific. Trehalose fluorescein 
isothiocyanate (Trehalose-FITC) Mw 731.7 Da was purchased from Kerafast.    
 
4.2.2 Delivery of trehalose into hASCs using microfluidic chips 
The same procedures reported in sections 3.1 and 3.2 of Chapter 3 were used to fabricate the silicon 
master molds necessary to manufacture the polydimethylsiloxane (PDMS) microfluidic chips. 
Specifically, microfluidic devices displaying a double deformation design with gaps of 8 μm in 
the deformation zones were selected for this investigation based on the optimization studies carried 
out in Chapter 3.  
hASCs (passages 2-5) were used for all the studies. Cells were cultured in T-75 flasks and collected 
by trypsinization when reaching 70-80% of confluency. After the neutralization and removal of 
trypsin, the cell pellet was resuspended in α-MEM and subdivided into aliquots containing 0.5 
×106 cells. hASCs were centrifuged at a speed of 1.5×103 g for 5 minutes. The media was 
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discarded, and the pellet was resuspended in 0.5 mL of low-conductive phosphate buffer (10 mM 
K2HPO4, 10 mM KH2PO4 and 1 mM MgCl2) containing different concentrations of trehalose (100, 
200, 250, and 300 mM). Cell diameter was measured with an automated cell counter to evaluate 
the effect of the osmotic pressure of the delivery medium. Three measurements were carried out 
for each cell suspension. The microfluidic chip was washed and pre-treated with the different 
trehalose solutions before the infusion of the cells. The cell suspension was then injected into the 
microfluidic chip at the constant flow rate of 150 µL/min using a microfluidic pump (Harvard 
Apparatus, MA, USA). hASCs were collected at the outlet and allowed to recover for 5 minutes 
post-treatment at room temperature. Subsequently, the cell suspension was centrifuged at 1.5×103 
g for 5 minutes, and the supernatant containing trehalose was carefully removed and stored for 
further quantification as reported in the following section. Cells were then resuspended in 0.5 mL 
of PBS 1X containing propidium iodide for 15 minutes at room temperature. The cell suspension 
was analyzed by flow cytometry to evaluate the percentage of cell death. 
 
4.2.3 Quantification and visualization of intracellular trehalose 
The amount of trehalose internalized by the cells was evaluated indirectly by measuring the 
concentration of trehalose before and after hASCs were squeezed in the microfluidic device. 
Precisely, trehalose was quantified by using a Megazyme trehalose assay (Megazyme International 
Ireland, Wicklow, Ireland) according to the instructions provided in the manufacturer’s protocol. 
Trehalose is first enzymatically converted into glucose by hydrolysis. Glucose is then 
phosphorylated into glucose-6-phosphate (G6P) by a hexokinase. Finally, G6P is converted into 
gluconate-6-phosphate by the enzyme glucose-6-phosphate dehydrogenase (G6P-DH) with the 
formation of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) which can be 
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detected by UV spectroscopy at 340 nm using a well plate reader. The results were calculated as 
the mean ± deviation standard (n=3).  
Finally, to visualize the presence of intracellular trehalose, the same experiment was carried out 
by delivering trehalose-FITC. Briefly, hASCs were suspended in a solution of trehalose-FITC at 
the concentration of 0.125 mg/mL in PBS 1X. Cells were infused in the microfluidic chip and 
collected at the outlet. After squeezing, hASCs were left for 5 minutes at room temperature in the 
presence of trehalose-FITC to allow the resealing of the membrane. hASCs were then centrifuged 
at the speed of 1.5×103 g for 5 minutes, and the trehalose-FITC solution was discarded. The pellet 
was resuspended in 0.35 mL of PBS 1X containing propidium iodide for 15 minutes at room 
temperature. Finally, 150 µL of a trypan blue 0.4% w/v solution was added to the cell suspension 
to quench the extracellular fluorescence of trehalose-FITC. The efficiency of the delivery of 
trehalose-FITC was evaluated by monitoring the percentage of fluorescent cells. The results were 
reported as the mean ± deviation standard (n=3). Similarly, hASCs loaded with trehalose-FITC 
were imaged using a fluorescent microscope (Evos Fl Auto, Life Sciences, USA), and 
corresponding bright-field images were taken to visualize the population of fluorescent cells. 
 
4.2.4 Cryopreservation of hASCs using trehalose 
hASCs 0.5×106 were loaded with trehalose (300 mM) by following the procedure reported in 
section 4.2.2. Cells were collected at the outlet of the microfluidic chip and allowed to reseal their 
membrane for 5 minutes at room temperature. Then, hASCs were centrifuged at 1.5×103 g for 5 
minutes, and the supernatant discarded. The pellet was resuspended in freezing media containing 
trehalose as the cryoprotectant agent to obtain a cell suspension of 1×106 cells/mL. The freezing 
media was made of DMEM, 10% FBS and trehalose included at different concentrations ranging 
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from 50mM to 600 mM. Cells were frozen at -80 °C for 24 hours using a ‘Mr. Frosty’ freezing 
container filled with isopropanol to allow the temperature to decrease constantly at the rate of 1 
°C/min. Subsequently, hASCs were stored in the liquid nitrogen for 24 hours. Additionally, hASCs 
were passed through the microfluid device without loading any trehalose intracellularly and frozen 
in the same freezing media containing trehalose. Finally, as a control group, hASCs cultured in 
flasks were collected by trypsinization and frozen at the cell density of 1×106/mL using DMEM, 
supplemented with 10% FBS and 10% DMSO. The cells were frozen following the same steps 
consisting of a slow freezing phase (1°C/min) at -80 °C for 24 hours, followed by a freezing step 
in liquid nitrogen.  
 
4.2.5 Assessment of cell viability, morphology, proliferation rate, and apoptosis post-
cryopreservation 
The following studies were carried out using hASCs frozen in DMSO (control group) and hASCs 
loaded with trehalose (300 mM) and frozen the freezing media supplemented with trehalose (400 
mM). The cryovials were removed from the liquid nitrogen tank and placed in a 37 °C beads bath 
for five minutes. The freezing media was diluted with an equal volume of fresh culture medium 
added to the cell suspension before centrifugation. The cells were resuspended in a PBS solution 
pH 7.4 supplemented with 1μL of a PI solution (100 μg/mL) for 15 minutes to assess cell viability. 
The percentage of dead cells post-thawing was quantified with flow cytometry analysis by 
measuring the amount of red fluorescent cells. Three different samples were assessed for each 
tested group.  
hASCs obtained from the two different groups were thawed and seeded at the cell density of 1×104 
cells/well in a 24 well-plate with flat and clear bottom. Cells were allowed to proliferate for 24 
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hours before staining to visualize their morphology. Cells were fixed with 4% paraformaldehyde 
for 5 minutes at 37 °C and permeabilized with 0.1% Triton-X100 for 10 minutes at room 
temperature. Samples were blocked with 5% normal goat serum at room temperature for 
45 minutes. Mouse anti-human Paxillin antibody (1:400 with 1% goat serum) was added to hASCs 
and left overnight at 4 °C. Goat anti-mouse AlexaFluor 594 (1:500 in 1% goat serum) was then 
added and left for one hour at room temperature. DAPI and phalloidin-AlexaFluor488 were used 
to counterstain nuclei and F-actin, respectively. Fluorescent images were taken for each sample 
with a fluorescent microscope (Evos Fl Auto) at 40 X. Images were processed using ImageJ 
software, which enabled the quantitation of the total area of adhesion sites. 
Furthermore, the proliferation rate of hASCs was monitored for 24 and 48 hours post-thawing 
using an MTS assay (Promega, USA). hASCs were seeded in 24 well plates at the cell density of 
25×103 cells/well. Cells were incubated with an MTS reagent (20 μL for every 100 μL of media) 
following the manufacturer’s instructions. The absorbance of the media supplemented with the 
reagent was monitored at 490 nm after 1 hour and 30 minutes of incubation at 37°C in the dark. 
Proliferation rate was calculated considering an average of 3 different samples for each group and 
normalizing the results to the number of cells quantified 24 hours post-thawing. A calibration curve 
ranging from 5×103 to 1×105 cells/well was created to accurately correlate the absorbance values 
with the number of cells.  
Finally, the population of apoptotic cells was determined by Annexin A5 staining and subsequently 
assessed by flow cytometry. Briefly, cells were thawed and seed in 12 well plates at the cell density 
of 1×105 cells/well. Cells were allowed to proliferate for 24 hours prior to the experiment. Briefly, 
hASCs were collected by trypsinization and resuspended in PBS at the cell density of 1×106 
cells/mL. Cells were stained with Annexin A5 following the instructions provided in the 
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manufacturer’s protocol and analyzed by flow cytometry. The results were reported as the mean ± 
standard deviation of three samples for each group.  
 
4.2.6 Analysis of stemness and pro-apoptotic genes post-cryopreservation  
The expression of key stemness markers was monitored by qPCR analysis to investigate whether 
the stemness of hASCs was preserved after being stored in freezing media supplemented with 
trehalose. Similarly, the expression of pro-apoptotic markers was investigated post-
cryopreservation. Briefly, cells were seeded in a 12-well plate for 48 hours after thawing. Three 
groups were tested including hASCs frozen in DMSO, hASCs loaded with trehalose and frozen in 
media containing the disaccharide. mRNA was extracted from the cells using an RNeasy Mini Kit 
(Qiagen) and quantified using a NanoDrop spectrophotometer. Next, the mRNA samples were 
converted to cDNA using the High-Capacity cDNA Conversion Kit. Finally, gene expression was 
measured using a mixture of predesigned primers and the KiCqStart SYBR Green Master Mix. 
The expression of the following stemness markers was assessed, including Klf4, Nanog, and Sox2. 
Similarly, the following pro-apoptotic genes such as BAD, BAX, BAK1, BBC3 were analyzed. All 
the reactions were performed using a Mastercycler RealPlex. The fold expression levels will be 
calculated using the relative ΔΔCt method (n=4). GAPDH was considered as the housekeeping 
gene, and results were normalized based on the gene expression of hASCs cryopreserved in 






4.2.7 Quantification and assessment of angiogenic growth factor activity by hASCs in vitro 
post-cryopreservation 
hASCs from the different groups were thawed and cultured in Rooster Bio medium containing 2% 
FBS at 37 °C and 5% CO2 for 24 hours and 48 hours. Cells were seeded in 24 well plates at the 
cell density of 5×104 cells/well. The conditioned media was collected, and the concentration of 
vascular endothelial growth factor (VEGF) was quantified using an ELISA kit (R&D Systems) 
(n=3) by following the manufacturer’s protocol. A calibration plot in the range from 33 pg/mL to 
1ng/mL was used to correlate the absorbance at 450 nm with the concentration of VEGF.  
Additionally, the conditioned media obtained from the different groups was tested for its efficacy 
in promoting the formation of tubular-like structures in vitro. Human umbilical vein endothelial 
cells (HUVECs) were seeded on a growth factor depleted Matrigel based on the manufacturer’s 
protocol. Briefly, 289 µL of growth factor depleted Matrigel Matrix (10 mg/mL), previously 
thawed overnight on ice, was added to a 24 well culture plate. The plate was then incubated at 
37°C for 60 minutes to allow the gel to form. HUVECs (1.2×105) were seeded on each gel. The 
media composition was varied according to the different groups. A negative control consisted of 
endothelial cell growth medium-2 bullet kit (EGM-2, Lonza) without VEGF and basic fibroblast 
growth factor (bFGF). As positive control cells were cultured on the Matrigel with Lonza Media 
EG2-bullet kit supplemented with all the angiogenic growth factors. As test groups, HUVECs were 
cultured in EGM-2 without angiogenic growth factor but supplemented with the condition 
containing VEGF at the concentration of 0.1 ng/mL. After 18 hours, bright field images of the 
endothelial networks were taken for each group and the total number of nodes, meshes, and 
segments, as well as the total segment length and the number of isolated segments were determined 
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using the Angiogenesis Analyzer for ImageJ. Results were obtained from the analysis of at least 
15 images for each group.  
 
4.2.8 Evaluation of the differentiation ability of hASCs post-cryopreservation 
These studies were carried out to compare the differentiation potential post-cryopreservation in 
vitro of hASCs frozen in media containing DMSO or trehalose. After thawing, hASCs were seeded 
at the cell density of 2.5×104 cells/well in DMEM supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin and streptomycin. When the cells reached 80% of confluency, the media 
was replaced with complete adipogenesis differentiation medium (1X StemPro® Adipocyte 
Differentiation Basal Medium, 1X StemPro® Adipocyte Supplement, and Gentamicin (10 mg/mL) 
reagent. The media was changed every other day for a total number of 10 days. As a negative 
control group, hASCs were cultured in DMEM 10% FBS and 1% penicillin-streptomycin for the 
entire duration of the study. On the last day of differentiation, the media was removed, and cells 
were washed with PBS. Cells were fixed with 4% paraformaldehyde for 5 minutes and washed 
with PBS. Subsequently, cells were treated with isopropanol 60% for 5 minutes. The presence of 
intracellular lipid droplets, which is indicative of adipogenic differentiation, was assessed by Oil 
Red O (Sigma Aldrich) staining. The Oil red Stock Solution was obtained by dissolving 60 mg of 
Oil Red O in 20 ml of 100% isopropanol. The suspension was mixed and allowed to sit for 20 min. 
Then, the Oil Red O stock solution was diluted in distilled water by mixing 3 parts of this solution 
with 2 parts of water. After 10 minutes, the suspension was filtered with a 0.22 μm syringe filter 
and used within 15 minutes. 400 μL of Oil Red O solution was added to each well for 20 minutes. 
Cells were imaged using a microscope with a color camera to visualize the stained lipid droplets.  
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Additionally, gene expressions of several markers involved in early adipogenesis phase were 
monitored by qPCR analysis following the same procedure reported in section 4.2.6. These genes 
include peroxisome proliferator-activated receptor gamma-2 (PPAR-2), lipoprotein lipase (LPL), 
adipocyte protein 2 (aP2), and GAPDH as the housekeeping gene. 
Osteogenic differentiation was also investigated. After thawing, hASCs were initially cultured as 
reported above, and the media was replaced with an osteogenic medium consisting of α-MEM, 
10% FBS, 1% penicillin-streptomycin, 50 μM ascorbic acid-2 phosphate, 10 mM β-
glycerophosphate, and 10 nM dexamethasone. The media was changed every other day for 14 
days. Alkaline phosphatase (ALP) enzymatic activity was measured at day 7 following a 
fluorometric assay (Abcam, USA). To measure the ALP activity, cells were centrifuged at 1,500 
rpm for 5 minutes, and the supernatant was removed. Cells were homogenized in ALP buffer 
following the steps described in the protocol provided by the kit. Fluorescence was measured using 
a microplate reader at the excitation of 360 nm and an emission wavelength of 440 nm (n=3).  
At day 14, the media was removed, and the cells were washed with PBS. The cells were fixed with 
4% paraformaldehyde for 5 minutes. After fixation, hASCs were washed twice with distilled water 
and were stained for intracellular calcium deposits with 2% Alizarin Red S solution for 2-3 
minutes. After washing the excess of staining the cells were imaged with a microscope equipped 
with a color camera. 
 
4.2.9 Statistical analysis 
Statistical analysis was carried out by performing a two-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison test, which was used to determine the presence of 
significant difference among the groups. A t-test was used to compare experiments between two 
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experimental groups. All statistical analyses were carried out with Graph-pad Prism Software 7. 
A p value less than 0.05 indicates statistical significance, which was displayed as *p < 0.05, 
**p < 0.01, ***p < 0.001. 
 
4.3 Results and discussion 
4.3.1 Intracellular delivery of trehalose using the microfluidic device 
To be effective as a cryoprotectant reagent, trehalose needs to be present both intracellularly and 
extracellularly as demonstrated in other studies [274, 290]. Trehalose contributes to the formation 
of a stable glassy state by establishing hydrogen bonds with the polar head functional groups of 
phospholipids and transmembrane proteins present in the plasma membrane [291]. This 
phenomenon can prevent damage to the cells during the freezing step and avoid adverse 
conformational changes in proteins. Based on this premisis, the first part of this study was focused 
on the optimization of the concentration of trehalose both extracellularly and intracellularly with 
the final objective to find an alternative to DMSO for stem cell banking. 
Trehalose is a disaccharide of glucose, and due to its hydrophilicity, it cannot diffuse through the 
cell membrane. To overcome this issue, we have investigated a novel and safe delivery method 
that should promote efficient internalization without eliciting any detrimental effect on cell 
functionality. Toward this goal, hASCs were forced to pass through micro-constrictions in a 
microfluidic chip that could generate transient pores in the cell membrane, as shown in the 
schematic (Figure 4.1A). These temporary defects in the cell membrane enable the passive 
diffusion of trehalose present in the delivery medium. Specifically, a squeezing gap of 8 μm, a 
flow rate of 150 μL/min, and a double deformation design were selected as the constant parameters 
of the microfluidic device in this study. These values were selected based on the best delivery 
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results obtained in Chapter 3. Additionally, we further proved in this work that the optimized 
microfluidic chip did not cause any significant cytotoxic or apoptotic effect. To prove this point, 
we investigated the cell proliferation rate and apoptosis of hASCs after being squeezed in the 
microfluidic device (passed), and the results were compared to cells without any treatment (not 
passed). A small increase in the cell apoptosis values from 7.4±1.4 % to 11.2 ± 1.4 % was observed 
as the cells were squeezed in the microfluidic device (Figure S4.1A). However, cells displayed a 
similar proliferation rate after 48 hours of culture for both groups suggesting that the process of 
squeezing did not hinder the cells proliferation potential of hASCs (Figure S4.1B).  
The amount of extracellular trehalose in the freezing media (DMEM containing 10% FBS) was 
optimized based on hASCs’ cell viability. Specifically, the concentration of trehalose was varied 
from 50 to 600 mM to determine the optimal amount of extracellular trehalose needed for effective 
cryopreservation. According to the results, the highest cellular viability was detected when 
trehalose was present in the freezing medium at a concentration of 400 mM (Figure 4.1B). 
Concentration higher than 400 mM were not selected as a decline in cell viability was observed 
probably due to the increase in osmotic pressure. This osmotic effect was verified indirectly by 
measuring the variation in cell diameter of hASCs once resuspended in the freezing media 
containing trehalose prior to freezing. A decrease from 16.9 ± 0.2 μm to 14.02 ± 0.3 μm was 
measured as the cells were exposed to freezing media  supplemented with 50 mM and 600 mM 
trehalose, respectively (Figure S4.2A).  
As the second step, we delivered trehalose intracellularly by varying its concentration from 100 
mM to 300 mM using a low conductive phosphate buffer (⁓50 mOsm/kg) [289]. The amount of 
trehalose delivered intracellularly was quantified indirectly by measuring the decrease in its 
concentration before and after squeezing the cells through the microfluidic device. As expected, 
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the amount of disaccharide delivered intracellularly was strictly dependent on the initial 
concentration used. The highest amount of trehalose delivered to the cells was 42.8 ± 5.76 mM, 
which was achieved by delivering trehalose at an initial concentration of 300 mM (Figure 4.1C). 
Aside from the concentration of trehalose, the cell diameter is another important parameter that 
can impact the process of squeezing and the corresponding internalization of the external cargo. 
The best delivery results are commonly achieved when cells are squeezed within a gap with a size 
equal to half of the value of their diameter [218]. The optimized microfluidic device used in this 
study possessed micro-constrictions with a gap size of 8±1 μm. This means that cells should 
display a diameter of 16 ± 1 μm to guarantee the maximum efficiency of delivery. The cell 
diameter was initially measured to assess any change induced by the different osmotic pressure of 
the trehalose solutions. Specifically, hypotonic (100 mM, ⁓150 mOsm/Kg and 200 mM ⁓250 
mOsm/kg), isotonic (250 mM ⁓290-300 mOsm/kg) and hypertonic (300 mM, ⁓350 mOsm/Kg) 
solutions were tested in this study. A constant decrease in cell diameter was observed from 21.7 ± 
0.5 μm to 15.1 ± 0.2 μm as the concentration of trehalose was increased, suggesting a change in 
osmotic pressure (Figure S4.2B). The low efficiency of internalization detected when using a 
solution of 100 mM of trehalose could be attributed to the largest cell diameter of hASCs in this 
delivery medium, which was equal to 21.7 ± 0.5 μm. This value is much higher than the optimal 
range of 16 ± 1 μm required to obtain a maximum delivery efficiency. On the contrary, the cell 
diameter was in the optimal range required for effective deformation using the designed 






4.3.2. Assessment of cell viability of hASCs loaded with trehalose 
Subsequently, cells loaded with trehalose were frozen in the freezing medium containing a 
constant concentration of extracellular trehalose of 400 mM, which was chosen based on the 
previous optimization. Cell viability was assessed by flow cytometry analysis immediately after 
thawing in the media. Interestingly, the cell viability of hASCs after cryopreservation was 
significantly improved once trehalose was delivered intracellularly. Specifically, only 55.2% of 
hASCs were still alive after cryopreservation when no trehalose was internalized in the cytosol. 
As the concentration of trehalose delivered was increased from 100 mM to 300 mM, a significant 
enhancement was detected up to 83% of cell viability (Figure 4.1D). Similar results were obtained 
for the 250 and 300 mM groups, although the amount of trehalose internalized intracellularly was 
32.97 ± 3.05 mM and 42.8 ± 5.76 mM, respectively (Figure 4.1C). hASCs cryopreserved using 
DMSO displayed the better results in terms of cell viability with a value of 92.5% although not 
statistically significant compared to 300 mM trehalose group (Figure 4.1D). Several studies have 
demonstrated that the required intracellular concentration of trehalose for effective 
cryopreservation of mammalian cells ranges from 100 to 200 mM [259, 292]. However, our results 
demonstrate that an intracellular concentration of 42.8 ± 5.76 mM was sufficient to provide 
effective cryoprotection of hASCs with similar results to the DMSO group. This difference 
observed in this study may be due to the type of cells investigated as well as the different method 
used for the delivery of trehalose.  
Finally, we demonstrated the intracellular presence of the disaccharide by delivering trehalose-
FITC into hASCs using the same strategy.  hASCs became fluorescent upon delivery of trehalose-
FITC. Corresponding bright-field and fluorescent images were taken to visualize the cells that 




Figure 4.1 Internalization of trehalose and quantification of intracellular delivery. A) Schematic 
is representing the process of cell squeezing necessary for the formation of transient pores in the 
cell membrane. These pores enable the passive diffusion of extracellular trehalose into the cells. 
B) Cell viability of hASCs assessed by flow cytometry to identify the optimal concentration of 
extracellular trehalose in the freezing medium, C) Quantification of intracellular delivery of 
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trehalose in hASCs (n=3). D) Cell viability of hASCs assessed by flow cytometry after 
cryopreservation. The amount of extracellular trehalose used in all the groups was 400 mM except 
for DMSO. E) Bright-field and corresponding fluorescent images of hASCs after delivery of 
trehalose-FTIC. Scale bars = 200 μm. F) Flow cytometry histograms comparing hASCs loaded 
with trehalose-FITC and without any treatment. The gate indicates the population of fluorescent 
cells that have internalized the disaccharide. Results are reported as mean ± standard deviation 
(n=3). * = p < 0.05 ** = p <0.01, *** p < 0.001, and n.s. indicates non-significant values. 
 
Precisely, 85.1% of the cell population was fluorescent after being squeezed through the 
microfluidic device in the presence of trehalose-FITC (Figure 4.1F). Overall, these results indicate 
that our proposed strategy is efficient in promoting the delivery of trehalose. An extracellular 
concentration of 400 mM and intracellular of 42.8 ± 5.76 mM of trehalose were sufficient to 
preserve the viability of hASCs after cryopreservation with similar results to DMSO. This set of 
parameters were used for the rest of the studies discussed in the following sections.  
 
4.3.3 Evaluation of morphology, proliferation rate, apoptosis, and stemness post- 
cryopreservation using trehalose 
Aside from cell viability, it was important to evaluate other cellular parameters after 
cryopreservation with trehalose. hASCs’ morphology was investigated after thawing the cells by 
immunofluorescence staining to visualize actin stress fibers and the expression of focal adhesion 
points. Specifically, we stained for the presence of paxillin, which is one of the main proteins 
present in the focal adhesion complexes of mammalian cells [293].  Cells cryopreserved in 
trehalose (400 mM extracellular, and 48.2 mM intracellularly) did not show any visible change in 
morphology compared to the cells cryopreserved in the freezing media containing 10% of DMSO 
(Figure 4.2A). Quantification of the total area of focal adhesions and cell area showed comparable 
results for both tested groups (Figure 4.2B-C). Similarly, the proliferation rate of the cells post-
cryopreservation was monitored by MTS assays  at 24 and 48 hours. Cells were able to proliferate 
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after 48 hours with an increase in their cell number of 2.3 ± 0.1 and 2.86 ± 0.6 times for the DMSO 
and trehalose group, respectively (Figure 4.2D). Furthermore, apoptotic cells were evaluated after 
48 hours post-thawing by flow cytometry analysis. Specifically, cells were stained with Annexin 
A5, which is a protein that binds to phosphatidylserine. This phospholipid is normally present in 
the cytosol side of the plasma membrane in healthy cells. On the contrary, cells undergoing a 
process of apoptosis start to expose this phospholipid on the extracellular side of their membrane 
that can be detected by staining with Annexin A5 and quantified by flow cytometry. A similar 
percentage of apoptotic cells was found in both groups with a value of 5.4 ± 0.3% and 6.2 ± 0.6 % 
for trehalose and DMSO group, respectively (Figure 4.2E). 
FACs results were further confirmed by evaluating the expression of pro-apoptotic genes after 24 
hours post-thawing. Precisely, we investigated the expression of several markers such as BAD, 
BAX, BAK1, and BBC3, and the results were normalized based on the gene expression of hASCs 
frozen in DMSO. No significant difference was found in the expression of these markers for both 
groups investigated (Figure 4.2F). Finally, we evaluated the expression of key markers that 
regulate stem cells’ stemness, including Sox2, Nanog, and Klf4 after 24 hours post-thawing. Also, 
for this investigation, no significant difference in the expression of these genes was detected 
(Figure 4.2G). Taken all together, this set of data demonstrate how hASCs cryopreserved with 
trehalose delivered intracellularly displayed a similar cellular behavior after thawing to the ones 
cryopreserved in DMSO. However, it should be noticed that further investigation is required to 
verify whether similar results can be obtained for longer times of storage (one month) since the 






Figure 4.2 Evaluation of stem cell morphology, proliferation rate, apoptosis, and stemness after 
cryopreservation using trehalose vs. DMSO. A) Immunofluorescence staining of hASCs 
cryopreserved with freezing media supplemented with trehalose (400 mM) and DMSO (10% v/v). 
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hASCs were loaded with trehalose intracellularly before cryopreservation by delivering 300 mM 
trehalose. Cells were stained with Alexa Fluor 488 Phalloidin to visualize actin stress fibers (green) 
and with Diamidino-2-phenylindole dilactate (DAPI) to stain the nuclei (blue). In addition, paxillin 
staining (red) was carried out to identify the area of focal adhesions. Scale bar = 50 µm. B) 
Quantification of the total area of focal adhesions expressed by hASCs cryopreserved with the two 
different types of freezing media. Results are calculated based on the red fluorescence intensity 
obtained from the immunofluorescent staining for paxillin expression (n=20). C) Quantification 
of cell area of hASCs for the two groups tested. Results are reported as mean ± standard deviation 
(n=17). D) MTS analysis of the cell proliferation rate of the two different groups calculated at 48 
hours post-thawing (n=3). Results were normalized based on the cell number obtained at 24 hours. 
E) The overlap between representative histogram plots obtained by flow cytometry displaying a 
similar population of apoptotic cells for both hASCs cryopreserved in freezing media containing 
DMSO and trehalose. The area in light blue defines the gate used to quantify the apoptotic cells 
stained with Annexin A5 (n=3). F) qPCR analysis of key genes involved in the process of apoptosis 
such as BAD, BAX, BAK1, and BBC3 24 hours post-cryopreservation for DMSO and trehalose. G) 
Relative expression of stemness genes (Sox2, Nanog, Klf4) over GAPDH (housekeeping gene) in 
hASCs after 24 hours post-cryopreservation. qPCR results are reported as mean ± standard 
deviation (n=3). * = p < 0.05 ** = p <0.01, and *** p < 0.001 (n=3).  
 
4.3.4 Evaluation of angiogenic growth factor secretion and pro-angiogenic potential post-
cryopreservation using trehalose 
One of the well-known features of hASCs is their ability to produce a milieu of angiogenic growth 
factors that are essential to regulate angiogenesis both in vitro and in vivo [294, 295]. Therefore, 
we verify whether hASCs’ angiogenic potential was still retained after cryopreservation by 
quantifying the amount of VEGF secreted after cryopreservation. The results were expressed as a 
fold increase at 48 hours and normalized to the amount of growth factor retrieved after 24 hours. 
According to the results, a higher increase in VEGF secretion was detected in the DMSO group at 
48 hours in comparison to hASCs frozen with trehalose (Figure 4.3A). As a control study, we also 
investigated whether the mechanical stress produced by the process of cell squeezing was able to 
influence VEGF secretion with respect to untreated hASCs. The fold increase of VEGF found in 
both groups tested at 48 hours was similar, indicating that the process of squeezing used to deliver 
trehalose did not alter the angiogenic potential of hASCs (Figure S4.3). 
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The angiogenic potential of the different secretome produced by hASCs was further investigated 
for their ability to modulate the reorganization of human umbilical vein endothelial cells 
(HUVECs) into tubular structures. Particularly, HUVECs were seeded on Matrigel hydrogels, and 
their network structure was monitored over the course of 18 hours. The medium used to culture 
HUVECs was supplemented with the secretome derived from the different groups of hASCs 
(trehalose vs. DMSO) cultured for 24 hours post-thawing. Bright-field images were taken to assess 
the morphology of HUVECs and verify the formation of a healthy ranched network. A positive 
and negative control were included in the study consisting of HUVECs cultured in Lonza medium 
with and without angiogenic growth factors, respectively. The morphology of the HUVECs’ 
network did not display significant differences among the groups except for the negative control 
where a poor connection and lack of interconnected segments was clearly evident after 18 hours 
(Figure 4.3B). 
A more detailed analysis was carried out by ImageJ to quantify several parameters such as the 
number of nodes, number of meshes, number of segments, the total segment length and the number 
of isolated segments (Figures 4.3C-G). Each one of these parameters is essential to define the 
connectivity of the network and the presence of tubular structures (meshes), which are indicative 
of a healthy vasculature network. On the contrary, the number of isolated segments should be as 
low as possible as it suggests the lack of connection among the branches of the network. As 
expected, the negative control displayed the lower values among all groups for all the parameters 
quantified except for the total number of isolated segments. No significant difference was detected 
between the trehalose and the DMSO groups except for the total segment length, which was found 
to be significantly higher in the DMSO group. Overall, these set of results suggest indirectly that 
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the angiogenic secretome derived from hASCs cryopreserved with trehalose has a similar 
angiogenic potential with respect to hASCs cryopreserved in DMSO.  
 
 
Figure 4.3 Assessment of the angiogenic potential of hASCs cryopreserved using trehalose vs. 
DMSO. A) Fold expression of VEGF secretion after 48 hours normalized to the amount of growth 
factor produced after 24 hours of culture. Results are reported as mean ± standard deviation (n=3). 
B) Bright-field images of HUVECs cultured on Matrigel and treated with different types of 
secretome derived from hASCs cryopreserved in freezing media supplemented with trehalose or 
DMSO. The negative control group was represented by endothelial cells cultured without any 
angiogenic growth factor. Scale bars = 400 µm. Image J quantification of several parameters 
regarding the network structure including C) number of nodes D) number of meshes E) number of 
segments F) total segments length in the network, and G) number of isolated segments. The results 




4.3.5 Evaluation of osteogenic and adipogenic differentiation potential of hASCs post-
cryopreservation using trehalose 
The final step of this investigation aimed to verify the differentiation potential of hASCs into 
osteogenic and adipogenic lineages in vitro post-cryopreservation with trehalose. The evaluation 
of osteogenic differentiation was monitored by assessing the presence of the enzyme alkaline 
phosphatase (ALP), which is generally considered as an early osteogenic marker of differentiation. 
The ALP activity measured after 7 days of osteogenic differentiation was found to be similar 
between the DMSO and the trehalose group (Figure 4.4A). Similarly, hASCs started to deposit a 
significant amount of intracellular calcium that was detected by alizarin red staining after 14 days 
post-differentiation. No difference in the amount of intracellular calcium deposits was visible in 
the stained images of the cells cryopreserved with DMSO and trehalose after 14 days (Figure 
4.4B). 
hASCs were also successfully differentiated towards adipogenic lineage after 10 days of culture 
in adipogenic medium. qPCR analysis of main adipogenic gene markers such as LPL, aP2, and 
PPARγ-2, which are commonly upregulated in adipocytes, were quantified and compared between 
the two groups tested. Although aP2 was found more expressed in hASCs cryopreserved in 
trehalose, the results were not statistically significant for any of the markers tested (Figure 4.4C). 
Similarly, hASCs adipogenic differentiation was evaluated by staining with Oil red O to visualize 
the presence of intracellular lipid-filled droplets. Overall, the DMSO and the trehalose groups 
displayed a similar level of staining after 10 days of adipogenic differentiation (Figure 4.4D). 
Finally, we also verified whether the process of squeezing used to deliver trehalose has any effect 
on the differentiation potential of hASCs prior to freezing. The same studies have been carried out 
comparing the osteogenic and adipogenic differentiation of hASCs passed through the microfluidic 
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device and untreated cells. No significant change was observed in ALP quantification on day 7 
and alizarin red staining at 14 days between the two group tested (Figure S4.4A-B). Similarly, the 
process of squeezing did not alter the ability of the cells to differentiate towards the adipogenic 
lineage and similar level of staining and expression of LPL, aP2, and PPAR-γ2 was found for both  
groups analyzed (Figure S4.4C-D).   
 
 
The results reported in this investigation are confirmed by other reports were trehalose was 
delivered intracellularly through alternative delivery methods. For instance, Dovgan et al. 
promoted the internalization of trehalose by electroporation in hASCs and found that the stem cells 
 
Figure 4.4 Assessment of osteogenic and adipogenic differentiation of hASCs cryopreserved 
with trehalose vs. DMSO. A) Alkaline phosphatase quantification of hASCs for the different 
groups after 7 days of osteogenic differentiation. B) Alizarin red staining to detect the presence 
of intracellular deposits of calcium in the different groups after 14 days of osteogenic 
differentiation. Scale bars = 200µm C) qPCR analysis of PPARγ-2, aP2, LPL genes, which are 
commonly upregulated during the process of adipogenic differentiation of stem cells after 10 
days. GAPDH was used as the housekeeping gene. Results are reported as mean ± deviation 
standard (n=3). * = p<0.05, ** = p<0.01 *** = p<0.001. D) Oil Red O staining of hASCs 
differentiated in the adipogenic medium after 10 days to visualize the presence of intracellular 
lipid-filled droplets.  
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were able to successfully differentiate similarly into osteogenic and adipogenic lineages [289]. 
Similarly, in another study by Rao et al., trehalose was delivered using chitosan nanoparticles into 
hASCs. After cryopreservation, hASCs displayed similar differentiation potential towards 
adipogenic, osteogenic, and chondrogenic lineages with respect to cells without any step of 
cryopreservation [241]. Overall, these recent studies, combined with the findings reported in this 




The findings reported in Chapter 4 highlights the possibility of delivering trehalose intracellularly 
using the optimized microfluidic device. This strategy is efficient and does not require any toxic 
carrier for the delivery of trehalose. The amount of disaccharide required to obtain the highest cell 
viability post-cryopreservation has been optimized both intracellularly and extracellularly. 
Precisely, an extracellular concentration of 400 mM and an intracellular amount of 42.8 ± 5.76 
mM were required to achieve the best results in terms of cell viability. 
Cells cryopreserved in trehalose displayed a similar proliferation rate, negligible apoptosis, and 
retention of stemness markers with similar results for the cells cryopreserved in DMSO. 
Additionally, the angiogenic potential of hASCs cryopreserved using trehalose was comparable to 
the cells frozen with DMSO as demonstrated by in vitro angiogenic assays. Finally, the osteogenic 
and adipogenic differentiation potential of hASCs in vitro was preserved after cryopreservation 
irrespective of the CPA used.  
In conclusion, further validation of these promising in vitro results should be provided by testing 
the in vivo efficacy of hASCs cryopreserved with trehalose. An example in this direction could be 
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the assessment of the angiogenic potential in vivo of hASCs when co-administered with endothelial 
cells to promote wound healing. Similarly, a complete transcriptome analysis of hASCs 
cryopreserved in trehalose and DMSO could be necessary to exclude any variation occurring 
during the freezing step in the gene expression of key markers, which are important regulators of 





















CHAPTER 5. Conclusions and future directions  
 
The work discussed in the previous chapters provides direct examples of how intracellular delivery 
is a powerful tool that can be optimized and controlled to obtain specific cellular responses based 
on the type of cargo delivered into the cytosol.  
Firstly, in Chapter 2, we have investigated a carrier-based strategy to deliver plasmid DNA into 
stem cells taking into consideration the stiffness of the substrates as a modulator of transfection 
efficiency. We have demonstrated how the cell microenvironment plays a crucial role in defining 
the efficiency of transfection when using Lipofectamine2000, which is a widely used lipid-based 
carrier for gene delivery. Interestingly, stiffer substrates can augment both the internalization of 
lipoplexes and the transfection efficiency of hASCs. Our findings suggest a direct correlation 
between the observed changes in cytoskeletal rearrangement and the internalization of the 
lipoplexes. Additionally, we observed how caveolae-mediated genes are upregulated in the hASCs 
cultured on the stiffer silicone substrates, thus confirming the role of actin as a key mediator in the 
internalization of plasmid lipoplexes. Finally, the results indicate how transfected hASCs seeded 
on more rigid substrates exhibited higher levels of VEGF expression when compared to hASCs 
cultured on softer hydrogels. 
Based on these promising results, ideally, the same strategy proposed in this study could be applied 
to other types of stem cells to enhance transfection efficiency by using Lipofectamine. Gathering 
evidence from different sources of stem cells could be useful to further validate the impact of our 
findings and extend the applicability of our strategy for gene delivery applications.  
Aside from the stiffness, other physical factors defining the properties of the cell-substrate can be 
varied at the same time to augment transfection efficiency. One interesting approach would be to 
modulate both the stiffness and the topography and verify whether this dual effect may be 
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beneficial in improving the internalization of the lipoplexes used in this study. Finally, to further 
expand the understanding of how stiffness influence cell transfection in hASCs it would be also 
important to carry out the same experiment in a 3D model with a range of hydrogels displaying 
the same value of stiffness (0.5 kPa to 32 kPa). Cells encapsulated in a 3D microenvironment 
commonly display a different ability to uptake extracellular cargo and numerous parameters such 
as porosity, degradability aside from the substrate stiffness may play a decisive role in defining 
the yield of transfection.    
Another important aim addressed in this dissertation was the design of a microfluidic device to 
promote the intracellular delivery of trehalose. The design of the microfluidic chip described in 
Chapter 3 was optimized to promote maximum intracellular delivery of external cargo and 
minimal cytotoxic effects. The efficiency of the microfluidic chips strictly depended on the gap 
size of the micro-constrictions, the molecular weight of the cargo delivered, and the design of the 
geometry used to fabricate the chip. Specifically, a gap size of 8 μm was found to be the optimal 
distance that promoted the maximum efficiency of internalization with minimal toxicity. Similarly, 
the double deformation design proved to be more effective than the single deformation strategy in 
enhancing the delivery of extracellular cargo. hASCs displayed minimal apoptosis and retained 
their stemness. 
The optimal microfluidic chip design was used to deliver trehalose intracellularly as discussed and 
studied in Chapter 4. hASCs loaded with trehalose could be successfully cryopreserved in freezing 
media containing 400 mM trehalose. Upon thawing similar cell viability, proliferation rate, 
morphology, percentage of apoptotic cells, and differentiation potential was found for both hASCs 
loaded with trehalose and hASCs cryopreserved in DMSO. These results indicate that trehalose 
was effective in preserving the hASCs’ functionality in vitro post cryopreservation. 
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Among different strategies for intracellular delivery of trehalose, our proposed method offers a 
carrier-free platform to deliver extracellular components without causing any cytotoxic effect. For 
instance, designed delivery platforms based on pH-responsive polymers and cell-penetrating 
peptides can be used to efficiently load high amounts of intracellular trehalose. However, the risk 
of cell toxicity remains a big challenge for the clinical translation of these strategies [285, 296]. 
Small transient pores are generated in the cell membrane by squeezing the cells through micron-
sized constrictions of desired geometry [170, 226, 297]. This process allows the internalization of 
extracellular materials into the cytoplasm without the need for a toxic carrier [227, 228].  
Similarly, trehalose could be delivered by mechanical disruption of the cell membrane using 
external energy sources, including ultrasound, electrical, and thermal stress [167, 287-289]. 
Unfortunately, some of these methods (such as electroporation) can cause membrane instability 
and protein denaturation, and hence, thorough optimization is needed [298, 299]. On the contrary, 
the mechanical disruption of the cell membrane described in this thesis is a reversible process that 
enables efficient internalization of extracellular components with minimal decrease in cell 
viability. Finally, the proposed carrier-free strategy could be potentially translated into clinical 
settings. Stem cells isolated from healthy subjects can be ideally treated with the designed 
microfluidic chip to deliver trehalose to millions of cells in a short amount of time (minutes). 
Following this step, stem cells can be cryopreserved for long-term storage without the use of any 
DMSO. However, post-thawed cells should be thoroughly washed to remove all trehalose both 
extracellularly and intracellularly. Additionally, the genetic profile of stem cells cryopreserved 
using trehalose should be monitored after several passages post-cryopreservation. 
It should also be noted that there are few limitations in using microfluidic chips for the delivery of 
trehalose. For instance, clogging of the microfluidic channels by larger cells during each 
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experiment is inevitable. This problem arises from the inhomogeneity in the diameter of the cell 
population. As a result, the same chip cannot be used for another experiment, and hence, it 
increases the time and labor for fabrication of more chips. The other limitation is instead associated 
with the fabrication of the microfluidic chips. Precisely, fabricating micron-sized features with an 
exact desirable length is merely possible. This shortcoming is caused by the limitation of 
instruments involved in the fabrication process, such as UV mask aligner and SU8 spin coater. 
These limitations should be taken to account when designing microfluidic chips to fabricate high 
throughput delivery platforms for cell therapy and other applications. 
Overall, the work presented in this thesis achieved two major milestones. The first main point is 
that transfection efficiency using lipid-based carrier can be augmented by increasing the stiffness 
of the substrate. This important concept could be potentially applied to other type of carrier-based 
strategies to improve the intracellular delivery of genetic material and advance the field of gene-
based therapies. Secondly, the work presented in this thesis is the first described attempt to deliver 
trehalose intracellularly by using a microfluidic chip. The investigated strategy is non-toxic to cells 
and can promote the successful cryopreservation of stem cells without any significant change in 
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Figure S2.1 Immunofluorescence staining of hASCs seeded on soft (0.5 kPa) and stiff (32 
kPa) substrates. Cells were stained with Alexa Fluor 488 Phalloidin to visualize actin stress 
fibers (green) and with Diamidino-2-phenylindole dilactate (DAPI) to stain the nuclei (blue). 
In addition, paxillin staining (red) was carried out to identify the area of focal adhesion. Scale 





















Figure S2.2 Calibration curve for plasmid internalization analyzed by qPCR. This curve was 
obtained by acquiring the corresponding threshold cycle for different concentration of GFP 














Figure S2.3 Effect of substrate stiffness on green fluorescent protein (GFP) expression on 
hASCs upon transfection with Lipofectamine2000®. A) FACs analysis of hASCs seeded 
on the two different substrates after being transfected with GFP plasmid. The population 
of GFP positive cells are indicated on the graph (pink area). B) Quantification of mean 
fluorescence intensity (MFI) of GFP positive hASCs obtained using FACs analysis. C) 
Percentage of transfected cells obtained by analyzing FACs data. Results are reported as 
mean ± standard deviation (n = 3) * = p < 0.05, ** = p < 0.01. D) Fluorescent images and 
corresponding phase contrast images of hASCs expressing GFP after 24 hours of 












Figure S3.1. COMSOL simulations of flow velocity in every channel of both single and double 
deformation devices. Insets show the uniform distribution of the fluid velocity in the channels 
for both devices. On the right, line graphs of the velocity magnitude along the three cross-
sections across the length of the device were plotted. The velocities remained the same 

















Figure S3.2 Flow cytometry analysis displaying endocytosis of Dex-FITC in hASCs. hASCs 
were treated with A) 3 kDa Dex-FITC and B) 70 kDa Dex-FITC. 150 µL of a trypan blue 0.4% 







Figure S3.3 Effect of gap size, flow rates, and geometry (single and double deformation) on 
the internalization of Dex-FITC into fibroblasts. A) and B) Delivery efficiency of Dex-FITC (3 
kDa) in fibroblasts using single and double deformation, respectively. Three different gaps (6, 
8 and 10 µm) and two different flow rates (150 µL/min and 300 µL/min) were tested for each 
design. C) and D) Delivery efficiency of Dex-FITC (70 kDa) using single and double 
deformation, respectively. A decrease in the percentage of positive fluorescent fibroblasts was 
found in all the gaps tested compared to the results reported for Dex-FITC 3 kDa. Results are 
reported as mean ± deviation standard (n =3). ψ and ω are used to indicate a significant change 
in delivery compared to gap 6 for the other two gaps at the flow rate of 150 µL/min and 300 
µL/min, respectively (p<0.05). β and λ are used to indicate a significant change in delivery 
compared to gap 8 for gap 10 at the flow rate of 150 µL/min and 300 µL/min, respectively 



















Figure S3.4 Green fluorescent protein (GFP) transfection of hASCs using the optimized 
microfluidic device. A) Normalized mean fluorescent intensity (MFI) of hASCs analyzed by 
flow cytometry. No significant difference in MFI values were observed between low (150 
µl/min) and high (300 µl/min) flow rates. B) Phase contrast (top) and corresponding fluorescent 

















Figure S3.5 Effect of gap size, flow rates, and geometry design on the viability of fibroblasts 
passing through the microfluidic device. A) and B) Percentage of cell viability obtained after 
passing the cells through the single and the double deformation design, respectively. Similar to 
the delivery efficiency tests, three different gaps (6, 8 and 10 µm), and two different flow rates 
(150 µL/min and 300 µL/min) were tested for each design.  Results are reported as mean ± 
deviation standard (n =3). ψ and ω are used to indicate a significant increase in cell viability 
compared to gap 6 for the other two gaps at a flow rate of 150 µL/min and 300 µL/min, 
respectively (p<0.05). β and λ are used to indicate a significant increase in cell viability 
compared to gap 8 for gap 10 at the flow rate of 150 µL/min and 300 µL/min, respectively 


























Figure S3.6 Relative expression of stemness genes (Sox2, Nanog, Klf4) over GAPDH in 
hASCs. The qPCR analysis was carried out on the cells squeezed through the microfluidic 
device (red bars) and compared to hASCs untreated (blue bars). The gene expression was 
monitored immediately after the process of deformation and 24 hours post-treatment. No 
significant difference in gene expression was observed at 0 and 24 hours between the two 
























Figure S4.1 Assessment of cell viability and apoptosis of hASCs after being squeezed in the 
optimized microfluidic device. A) MTS analysis of the cell proliferation rate of hASCs after 
passing through the microfluidic device (passed) compared to untreated hASCs (not passed) 
Results were normalized based on the cell number obtained at 24 hours B) Quantification of 
apoptotic cells by flow cytometry analysis of hASCs after being passed through the microfluidic 
device The results were compared to untreated hASCs (not passed). (n=3). * = p < 0.05 ** = p 





























Figure S4.2 Cell diameter measurements in different concentrations of trehalose A) Cell 
diameter measurements of hASCs exposed to freezing media supplemented with different 
concentrations of trehalose ranging from 50 to 600 mM. B) Cell diameter measurements of 
hASCs exposed to phosphate buffer (10 mM K2HPO4, 10 mM KH2PO4 and 1 mM MgCl2) 
supplemented with different concentrations of trehalose varying from 0 to 300 mM. Results are 































Figure S4.3 Evaluation of the angiogenic potential of hASCs after squeezing. A) Fold 
expression of VEGF secretion after 48 hours normalized to the amount of growth factor 
produced after 24 hours of culture. The two groups tested are hASCs passed and not passed 
through the microfluidic device. Results are reported as mean ± standard deviation (n=3). * = 
p < 0.05 ** = p <0.01, and *** p < 0.001. B) Bright-field images of HUVECs cultured on 
Matrigel and treated with different types of secretome derived from hASCs passed and not 
passed through the microfluidic device. The negative control group was represented by 



















Figure S4.4 Assessment of osteogenic and adipogenic differentiation of hASCs after being 
squeezed in the optimized microfluidic device. A) Alkaline phosphatase quantification of 
hASCs for the different groups after 7 days of osteogenic differentiation. Scale bar = 200 µm. 
The results are reported as mean ± deviation standard (n=3). * = p<0.05, ** = p<0.01 *** = 
p<0.001. B) Alizarin red staining to detect the presence of intracellular deposits of calcium in 
the different groups after 14 days of osteogenic differentiation. C) qPCR analysis of PPARγ-2, 
aP2, LPL genes, which are commonly upregulated during the process of adipogenic 
differentiation of stem cells after 10 days. Results are reported as mean ± deviation standard 
(n=3). * = p<0.05, ** = p<0.01 *** = p<0.001. D) Oil Red O staining of hASCs differentiated 
in the adipogenic medium after 10 days to visualize the presence of intracellular lipid-filled 
droplets in hASCs passed through the microfluidic device compared to untreated cells.  
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Table S2.1. Main genes regulating the process of Caveolin-mediated endocytosis 
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Table S2.2 Main genes regulating the process of Clathrin-mediated endocytosis. 




Main component of clathrin 
triskelion formation 
SNX9 GGAATGGAAAACTGGAAAGAG TCTACTAAGTCCAAGTCAGG 
Involved in clathrin-coated vesicle 
budding and formation of the 
clathrin neck  
EPS15 AAGGTCAACAATGAAGATCC GACCGATGTTTCCTCAAATAC 
A scaffolding protein, Involved in 




An accessory protein which 
mediates clathrin binding to cell 



















Table S3.1 Comparison of the percentage of 3-kDa Dex-FITC delivery in hASCs for single and 












































20.68 ± 8.19 47.21 ± 11.19 0.0296* 28.07 ± 6.96 49.28 ± 17.06 0.1169 
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97.42 ± 0.68 98.21 ± 0.37 0.1519 96.70 ± 0.48 96.11 ± 1.84 0.6195 
